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MODULATION OF LIPID METABOLISM FOR PROTEIN PRODUCTION
RELATED APPLICATIONS
This application claims priority to U.S. Serial No.: 62/330973, filed May 3, 2016, the
entire contents of which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
The present disclosure relates to methods and compositions for modulating the lipid
metabolism pathways of a cell and engineering cells and cell lines for production of a product,
e.g., a recombinant protein.
BACKGROUND
Recombinant therapeutic proteins are commonly expressed in cell expression systems,
e.g., mammalian cell expression systems. In 2014, the total number of market approved
biopharmaceuticals was 212, and 56% of the therapeutic products approved for market by the
FDA are produced in mammalian cell lines. However, the high cost associated with production
contributes to increasing global health costs.
Moreover, next generation protein biologies (NGBs) such as next generation fusion
proteins, multimeric glycoproteins, or next generation antibodies often have a complex and/or
non-natural structure and are proving more difficult to express than molecules such as
monoclonal antibodies. Current host cell lines have not evolved pathways for the efficient
synthesis and secretion of NGBs, resulting in significantly reduced growth, low productivity and
often resulting in products with poor product quality attributes. Thus, these NGBs are
considered difficult to express, in which the productivity and product quality do not meet clinical
and market needs.
Accordingly, there is an increasing need to develop and produce recombinant
biotherapeutics rapidly, efficiently, and cost-effectively while maintaining final product quality.
SUMMARY
The present disclosure is based, in part, on the discovery that modulation of lipid
metabolism pathways by overexpression of a component of one or more lipid metabolism
pathways increases the productivity and product quality of a cell that produces a recombinant
polypeptide product. Here, it is demonstrated that modulation of the lipid metabolism, e.g., by
modulating one or more lipid metabolism pathways, can be used to engineer cells and cell-free
systems that produce higher yields of products and products with improved quality. Importantly,
the present disclosure features global regulation of lipid metabolism by using global regulators
that modulate more than one process or pathway associated with lipid metabolism, thereby
causing multiple downstream effects to achieve improved product production and quality. The
methods and compositions described herein are particularly useful for improved production of
recombinant products or next generation biologies (e.g., fusion proteins, bispecific or multi-
format antibody molecules, multimeric proteins, and glycosylated proteins), and for development
of more efficient systems for production of such products (e.g., cell lines or cell-free systems).
In one aspect, the present disclosure features a method for producing a product described
herein in a cell. In an embodiment, the product is a polypeptide, e.g., a recombinant
polypeptide. In one embodiment, the method comprises providing a cell comprising a
modification that modulates lipid metabolism, and culturing the cell, e.g., under conditions
suitable for modulation of lipid metabolism by the modification, thereby producing the product.
In another aspect, the present disclosure features a method for producing product, e.g., a
polypeptide, e.g., a recombinant polypeptide, in a cell-free system comprising: providing a cell-
free system comprising a modification that modulates lipid metabolism, e.g., a cell-free system
derived from a cell or cell line comprising a modification that modulates lipid metabolism, and
placing the cell-free system under conditions suitable for production of the product; thereby
producing the product, e.g., polypeptide, e.g., recombinant polypeptide. In one embodiment, the
cell-free system is derived from a cell or cell line comprising a modification that modulates lipid
metabolism. In one embodiment, the cell-free system comprises one or more components, e.g.,
an organelle or portion of an organelle, from a cell or cell line comprising a modification that
modulates lipid metabolism. In some embodiments, the modification comprises an exogenous
nucleic acid encoding a lipid metabolism modulator (LMM) and wherein the cell or cell line
expresses a LMM, e.g., an LMM selected from the group consisting of SREBF1, SREBF2,
SCDl, SCD2, SCD3, SCD4, SCD5, or a functional fragment thereof. In some embodiments, the
LMM alters one or more characteristics of a cell-free system selected from the group consisting
of: increases the production, e.g., yield and rate of production, of the product, e.g., polypeptide,
e.g., recombinant polypeptide ( GB) produced; and increases the quality, e.g., decreases
aggregation, decreases glycosylation heterogeneity, decreases fragmentation, and increases ratio
of properly folded to misfolded or unfolded product, of the product.
Examples of products that can be produced using any of the methods or compositions
described herein include recombinant products, or products in which at least one portion or
moiety is a result of genetic engineering. Recombinant products described herein can be useful
for diagnostic or therapeutic purposes. In one embodiment, a product comprises a polypeptide,
such as an antibody molecule (e.g., a bispecific or multi-format antibody molecule), a fusion
protein, or a protein-conjugate; a nucleic acid molecule (e.g., a DNA or R A molecule); or a
lipid-encapsulated particle (e.g., an exosome or virus-like particle). The methods and
compositions described herein may be particularly useful for products that are difficult to
produce, e.g., in high quantities or with sufficient quality for commercial or therapeutic use, such
as next generation biologies (e.g., fusion proteins, bispecific or multi-format antibody molecules,
multimeric proteins, and glycosylated proteins). In one embodiment, a cell as described herein,
e.g., for producing the product, expresses the product. In one embodiment, the cell comprises an
exogenous nucleic acid that encodes a product described herein, e.g., a polypeptide selected from
Table 2 or 3. Additional examples of products are described in the section titled "Products".
The modifications disclosed herein that modulate lipid metabolism include agents or
molecules that increase or decrease the expression of a lipid metabolism modulator (LMM) or
increase or decrease the expression or activity of a component of a lipid metabolism pathway. In
one embodiment, the modification is a nucleic acid, e.g., a nucleic acid encoding a LMM or an
inhibitory nucleic acid that inhibits or decreases the expression of a LMM.
In one embodiment, the modification increases expression of a LMM, and comprises an
exogenous nucleic acid encoding the LMM. In one embodiment, the method comprises forming,
in the cell, an exogenous nucleic acid encoding a LMM or an exogenous LMM. In one
embodiment, the forming comprises introducing an exogenous nucleic acid encoding a lipid
metabolism modulator. In one embodiment, the forming comprises introducing an exogenous
nucleic acid which increases the expression of an endogenous nucleic acid encoding a LMM.
Examples of LMMs suitable for use in any of the methods and compositions described herein are
further described in the sections titled "Modulation of Lipid Metabolism" and "Lipid Metabolism
Modulators".
In one embodiment, the cell comprises one or more modifications. In one embodiment,
the cell comprises one, two, three, four, five, six, seven, eight, nine or ten modifications. In some
embodiments, the cell comprises more than one modification. In some embodiments, the cell
comprises at least two, three, four, five, six, seven, eight, nine, or ten modifications. In one
embodiment, the cell comprises a one or more second modification that modulates lipid
metabolism. In one embodiment, the second modification comprises a second exogenous nucleic
acid encoding a second LMM, e.g., a LMM different from the LMM of the first modification. In
one embodiment, the second exogenous nucleic acid and the first exogenous nucleic acid are
disposed on the same nucleic acid molecule. In one embodiment, the second exogenous nucleic
acid and the first exogenous nucleic acid are disposed on different nucleic acid molecules. In one
embodiment, the second modification provides increased the production or improved quality of
the product, as compared to a cell not having the second modification. In one embodiment, the
method comprises forming, in the cell, a second exogenous nucleic acid encoding a second
LMM or a second exogenous LMM. In one embodiment, the forming comprises introducing the
second exogenous nucleic acid encoding a second LMM. In one embodiment, the forming
comprises introducing the second exogenous nucleic acid which increases the expression of an
endogenous nucleic acid encoding a LMM.
Modulating lipid metabolism by any of the methods or compositions described herein can
comprise or result in altering, e.g., increasing or decreasing, any one or more of the following:
i) the expression (e.g., transcription and/or translation) of a component involved in a
lipid metabolism pathway;
ii) the activity (e.g., enzymatic activity) of a component involved in a lipid
metabolism pathway;
iii) the amount of lipids (e.g., phospholipids, or cholesterol) present in a cell;
iv) the amount of lipid rafts or rate of lipid raft formation;
v) the fluidity, permeability, and/or thickness of a cell membrane (e.g., a plasma
membrane, a vesicle membrane, or an organelle membrane);
vi) the conversion of saturated lipids to unsaturated lipids or conversion of
unsaturated lipids to saturated lipids;
vii) the amount of saturated lipids or unsaturated lipids, e.g., monounsaturated lipids;
viii) the composition of lipids in the cell to attain a favorable composition that
increases ER activity;
ix) the expansion of the ER (e.g., size of the ER, the ER membrane surface, or the
amounts of the proteins and lipids that constitute and/or reside within the ER);
x) the expansion of the Golgi (e.g., the number and size of the Golgi, the Golgi
surface, or the number or amounts of proteins and molecules that reside within the
Golgi);
xi) the amount of secretory vesicles or the formation of secretory vesicles;
xii) the amount or rate of secretion of the product;
xiii) the proliferation capacity, e.g., the proliferation rate;
xiv) culture viability or cell survival;
xv) activation of membrane receptors;
xvi) the unfolded protein response (UPR);
xvii) the yield or rate of production of the product;
xviii) the product quality (e.g., aggregation, glycosylation heterogeneity, fragmentation,
proper folding or assembly, post-translational modification, or disulfide bond
scrambling); and /or
xix) cell growth/proliferation or cell specific growth rate.
In such embodiments, the increase or decrease of any of the aforementioned characteristics of the
cell can be determined by comparison with a cell not having a modification.
The methods and compositions described herein result in increased production of the
product as compared to a cell not having the modification. An increase in production can be
characterized by increased amounts, yields, or quantities of product produced by the cell and/or
increased rate of production, where the rate of production is equivalent to the amount of product
over time. In one embodiment, production of the product, e.g., a recombinant polypeptide, is
increased by 1%, 5%, 10%, 15%,20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 70%, 75%,
80%, 85%, 90%, 85%, or 100%, or more e.g., as compared to the production of by a cell without
modulation of the lipid metabolism; or 1-fold, 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold,
e.g., as compared to the production of by a cell without modulation of the lipid metabolism.
The methods and compositions described herein can also result in improved quality of the
product (i.e. product quality) as compared to a cell not having the modification. Improvements in
the quality of the product (i.e. product quality) can be characterized by one or more of:
aggregation (e.g., a decrease in aggregates or aggregation); proper folding or assembly (e.g., a
decrease in misfolded or unfolded products; or partially assembled or disassembled products);
post-translation modification (e.g., increase or decrease in glycosylation heterogeneity, higher
percentage of desired or predetermined post-translational modifications); fragmentation (e.g., a
decrease in fragmentation); disulfide bond scrambling (e.g., a decrease in undesired isoforms or
structures due to disulfide bond scrambling). In one embodiment, the quality of the product, e.g.,
recombinant polypeptide, is increased, e.g., 1%, 5%, 10%, 15%,20%, 25%, 30%, 35%, 40%,
45%, 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 85%, or 100%, e.g., as compared to the
production of by a cell without modulation of the lipid metabolism; or by 1-fold, 2-fold, 5-fold,
10-fold, 20-fold, 50-fold, 100-fold, e.g., as compared to the quality of product produced by a cell
without modulation of the lipid metabolism.
In embodiments, the method for producing a product as described herein can comprise
one or more additional steps, which include, but are not limited to: introducing a modification to
the cell that improves ER processing capacity (ER expansion) or secretion; obtaining the product
from the cell, or a descendent of the cell, or from the medium conditioned by the cell, or a
descendent of the cell; separating the product from at least one cellular or medium component;
and/or analyzing the product, e.g., for activity or for the presence of a structural moiety. In one
embodiment, the method further comprises a step for improving ER processing capacity (or ER
expansion) by introducing a nucleic acid encoding PDI, BiP, ERO, or XBP1. In one
embodiment, the method further comprises an additional step for improving secretory capacity or
rate of secretion by modulating SNARE machinery or other machinery involved in the secretory
pathway, e.g., by introducing a nucleic acid encoding a SNARE component.
Modulation of Lipid Metabolism
The present disclosure features methods and compositions for modulating lipid metabolism.
In one embodiment, the modification results in modulating, e.g., increasing, one or more lipid
metabolism pathways, which include, but are not limited to: de novo lipogenesis, fatty acid re-
esterification, fatty acid saturation or desaturation, fatty acid elongation, and phospholipid
biosynthesis.
The modifications described herein suitable for modulating lipid metabolism include
introduction of an exogenous nucleic acid that increase or decreases the expression or activity of
a component of a lipid metabolism pathway or a LMM, a LMM polypeptide, or other molecule
that increases or decreases the expression or activity of a component of the lipid metabolism
pathway. The present disclosure features the use of lipid metabolism modulators to modulate
lipid metabolism, e.g., by increasing or decreasing expression or activity of a component
associated with lipid metabolism. In an embodiment, the LMM is a global regulator described
herein
In one embodiment, the modification that modulates lipid metabolism results in the
global regulation of lipid metabolism, e.g., by increasing or decreasing the expression or activity
of a global regulator. Such global regulators are molecules that are sufficiently upstream in one
or more pathways, such that it can influence multiple downstream effects, for example,
increasing the expression or activity of more than one, e.g., two, three, four, five, or more,
components of different lipid metabolism processes or pathways. A component of a lipid
metabolism process or pathway can include, but is not limited to, an enzyme, a cofactor, or other
molecule that is involved in the synthesis, degradation, elongation, or structural conformation of
lipid molecules.
In one embodiment, the global regulator described herein is a transcription factor that
upregulates, e.g., increases the expression, of a component of the lipid metabolism, e.g., a lipid
metabolism gene product selected from Table 1. By way of example, a global regulator
increases the expression of two or more lipid-associated gene products, e.g., an enzyme involved
in lipid biosynthesis and an enzyme involved in the saturation level of a lipid molecule.
In any of the methods or compositions described herein, the LMM comprises any of the
following: a global regulator of lipid metabolism, e.g., a transcription factor that upregulates
lipid metabolism genes, or a component (e.g., an enzyme, a cofactor, or a molecule) that plays a
role in the de novo lipogenesis, fatty acid re-esterification, fatty acid saturation or desaturation,
fatty acid elongation, or phospholipid biosynthesis pathways.
In one embodiment, the lipid metabolism modulator comprises a transcription regulator,
e.g., a transcription factor, that mediates, e.g., upregulates, the expression of a lipid metabolism
gene product. Examples of lipid metabolism gene products include, but are not limited to, those
provided in Table 1. a global regulator of lipid metabolism, e.g., a transcription factor that
upregulates lipid metabolism genes.
In one embodiment, the LMM comprises SREBF1, or SREBF2, or a functional fragment
or analog thereof. In one embodiment, the lipid metabolism modulator comprises at least 60,
70, 80, 90, 95, 98, 99 or 100% identity with the amino acid sequence of SREBF1; e.g., SEQ ID
NOs:l or 34, or a functional fragment thereof, e.g., SEQ ID NO: 26, SEQ ID NO: 27, or SEQ ID
NO: 36; or differs by 1, 2, or 3 or more amino acid residues but no more than 50, 40, 30, 20, 15,
or 10 amino acid residues from the amino acid sequence of SREBF1, e.g., SEQ ID NOs: 1 or 34,
or a functional fragment thereof, e.g., SEQ ID NO: 26, SEQ ID NO: 27, or SEQ ID NO: 36. In
one embodiment, the nucleic acid encoding the lipid metabolism modulator comprises at least
60, 70, 80, 90, 95, 98, 99 or 100% identity with any of the nucleic acid sequences selected from
SEQ ID NOs: 2 or 32, or the nucleic acids encoding SEQ ID NO: 26, SEQ ID NO: 27, or SEQ
ID NO: 36.
In one embodiment, the LMM comprises SCD1, SCD2, SCD3, SCD4, or SCD5, or a
functional fragment or analog thereof. In one embodiment, the lipid metabolism modulator
comprises at least 60, 70, 80, 90, 95, 98, 99 or 100% identity with the amino acid sequence of
SCD1; e.g., SEQ ID NO:3, or a functional fragment thereof; or differs by 1, 2, or 3 or more
amino acid residues but no more than 50, 40, 30, 20, 15, or 10 amino acid residues from the
amino acid sequence of SCD1, e.g., SEQ ID NO: 3, or a functional fragment thereof. In one
embodiment, the nucleic acid encoding the lipid metabolism modulator comprises at least 60, 70,
80, 90, 95, 98, 99 or 100% identity with any of the nucleic acid sequences selected from SEQ ID
NOs: 4 .
In one embodiment, the LMM comprises any of the components provided in Table 1 or a
functional fragment thereof. In one embodiment, the LMM comprises at least 60, 70, 80, 90, 95,
98, 99 or 100% identity with the amino acid sequence of any of the components provided in
Table 1 or a functional fragment thereof; or differs by 1, 2, or 3 or more amino acid residues but
no more than 50, 40, 30, 20, 15, or 10 amino acid residues from the amino acid sequence of any
of the components provided in Table 1 or a functional fragment thereof. In one embodiment, the
nucleic acid encoding the lipid metabolism modulator comprises at least 60, 70, 80, 90, 95, 98,
99 or 100% identity with a nucleic acid sequence encoding any of the components provided in
Table 1 or a functional fragment thereof.
In one embodiment, the modification comprises a cis or trans regulatory element that
increases the expression of a nucleic acid that encodes a lipid metabolism gene product, e.g., a
lipid metabolism gene product selected from Table 1.
In one embodiment, the nucleic acid encoding the lipid metabolism modulator comprises
a plasmid or a vector.
In one embodiment, the nucleic acid encoding the lipid metabolism modulator is
introduced into the cell by transfection (e.g., electroporation), transduction, or any other delivery
method described herein.
In one embodiment, the nucleic acid encoding the lipid metabolism modulator is
integrated into the chromosomal genome of the cell. In one embodiment, the LMM is stably
expressed.
In one embodiment, the nucleic acid encoding the lipid metabolism modulator is not
integrated into the chromosomal genome of the cell. In one embodiment, the LMM is transiently
expressed.
Products
Products described herein include polypeptides, e.g., recombinant proteins; nucleic acid
molecules, e.g., DNA or R A molecules; multimeric proteins or complexes; lipid-encapsulated
particles, e.g., virus-like particles, vesicles, or exosomes; or other molecules, e.g., lipids. In an
embodiment, the product is a polypeptide, e.g., a recombinant polypeptide. For example, the
recombinant polypeptide can be a difficult to express protein or a protein having complex and/or
non-natural structures, such as a next generation biologic, e.g., a bispecific antibody molecule, a
fusion protein, or a glycosylated protein.
In any of the methods described herein, the method for producing a product further
comprises introducing to the cell an exogenous nucleic acid encoding the product, e.g.,
polypeptide, e.g., recombinant polypeptide.
In one embodiment, the exogenous nucleic acid encoding the recombinant polypeptide is
introduced after providing a cell comprising a modification that modulates lipid metabolism. In
another embodiment, the exogenous nucleic acid encoding the recombinant polypeptide is
introduced after culturing the cell, e.g., under conditions suitable for modulation of lipid
metabolism by the modification.
In one embodiment, the exogenous nucleic acid encoding the product, e.g., recombinant
polypeptide, is introduced prior to providing a cell comprising a modification that modulates
lipid metabolism. In another embodiment, the exogenous nucleic acid encoding the recombinant
polypeptide is introduced prior to culturing the cell, e.g., under conditions suitable for
modulation of lipid metabolism by the modification.
In any of the compositions, preparations, or methods described herein, the product, e.g.,
recombinant polypeptide, is a therapeutic polypeptide or an antibody molecule, e.g., an antibody
or an antibody fragment thereof. In one embodiment, the antibody molecule is a monoclonal
antibody. In one embodiment, the antibody molecule is a bispecific antibody molecule, e.g., a
BiTE (Bispecific T cell Engager), a DART (Dual Affinity Re-Targeting or Redirected T cell).
In one embodiment, the product, e.g., recombinant polypeptide, is selected from Table 2
or 3 .
In embodiments, the product is stably expressed by the cell. In one embodiment, the
exogenous nucleic acid encoding the product, e.g., recombinant polypeptide, is integrated into
the chromosomal genome of the cell. Alternatively, the product is transiently expressed by the
cell. In one embodiment, the exogenous nucleic acid encoding the product, e.g., the recombinant
polypeptide, is not integrated into the chromosomal genome of the cell.
Host Cells
Provided herein are cells for producing the products described herein and methods of
engineering such cells.
In any of the compositions, preparations, or methods described herein, the cell is a
eukaryotic cell. In one embodiment, the cell is a mammalian cell, a yeast cell, an insect cell, an
algae cell, or a plant cell. In one embodiment, the cell is a rodent cell. In one embodiment, the
cell is a Chinese hamster ovary (CHO) cell. Examples of CHO cells include, but are not limited
to, CHO-K1, CHOK1SV, Potelligent CHOK1SV (FUT8-KO), CHO GS-KO, Exceed
(CHOK1SV GS-KO), CHO-S, CHO DG44, CHO DXB1 1, CHOZN, or a CHO-derived cell.
In any of the compositions, preparations, or methods described herein, the cell is selected
from the group consisting of HeLa, HEK293, H9, HepG2, MCF7, Jurkat, NIH3T3, PC12,
PER.C6, BHK, VERO, SP2/0, NSO, YB2/0, EB66, C127, L cell, COS, e.g., COS1 and COS7,
QCl-3, CHO-K1, CHOK1SV, Potelligent CHOK1SV (FUT8-KO), CHO GS-KO, Exceed
(CHOK1 SV GS-KO), CHO-S, CHO DG44, CHO DXB 11, and CHOZN.
In one embodiment, the cell is a eukaryotic cell other than a mammalian cell, e.g., an
insect, a plant, a yeast, or an algae cell. In one embodiment, the cell is a prokaryotic cell.
In one aspect, the present disclosure features a method of engineering a cell having
increased production capacity and/or improved quality of production (e.g., producing product
with one or more improved product quality) comprising introducing to the cell or forming in the
cell an exogenous nucleic acid encoding a lipid metabolism modulator, thereby engineering a
cell having increased production capacity and/or improved quality of production . In an
embodiment, the exogenous nucleic acid encoding a lipid metabolism modulator is introduced to
the cell by transfection, transduction, e.g., viral transduction, electroporation, nucleofection, or
lipofection. In an embodiment, the exogenous nucleic acid encoding a lipid metabolism
modulator is integrated into the chromosomal genome of the cell. In an embodiment, the method
further comprises introducing to the cell an exogenous nucleic acid encoding a recombinant
polypeptide. In an embodiment, the exogenous nucleic acid encoding a recombinant polypeptide
is introduced prior to introducing the exogenous nucleic acid encoding the LMM. In an
embodiment, the exogenous nucleic acid encoding a recombinant polypeptide is introduced after
introducing the exogenous nucleic acid encoding the LMM.
In one aspect, the present disclosure features a cell produced by providing a cell and
introducing to the cell a LMM described herein, e.g., introducing an exogenous nucleic acid
encoding a LMM.
In one aspect, the present disclosure features a cell comprising an exogenous nucleic acid
encoding a LMM described herein
In one aspect, the present disclosure features a cell engineered to produce a LMM,
wherein the LMM modulates the expression of a product, e.g., a next generation biologic ( GB)
described herein. In one embodiment, the cell is a CHO cell.
In one aspect, the present disclosure features a CHO cell engineered to produce a LMM,
wherein the LMM modulates the expression of a product, e.g., a Next generation biologic (NGB)
described herein.
In one aspect, the present disclosure features a CHO cell engineered to express an LMM
and a NGB, wherein the population has been selected for high level expression of the NGB.
In one aspect, the present disclosure features a CHO cell engineered to express an LMM,
wherein the LMM modulates one or more characteristics of the CHO cell, wherein the
engineered CHO cell is selected based on modulation of one or more characteristics selected
from the group consisting of
i) the expression (e.g., transcription and/or translation) of a component involved in a
lipid metabolism pathway;
ii) the activity (e.g., enzymatic activity) of a component involved in a lipid
metabolism pathway;
iii) the amount of lipids (e.g., phospholipids, or cholesterol) present in a cell;
iv) the amount of lipid rafts or rate of lipid raft formation;
v) the fluidity, permeability, and/or thickness of a cell membrane (e.g., a plasma
membrane, a vesicle membrane, or an organelle membrane);
vi) the conversion of saturated lipids to unsaturated lipids or conversion of
unsaturated lipids to saturated lipids;
vii) the amount of saturated lipids or unsaturated lipids, e.g., monounsaturated lipids;
viii) the composition of lipids in the cell to attain a favorable composition that
increases ER activity;
ix) the expansion of the ER (e.g., size of the ER, the ER membrane surface, or the
amounts of the proteins and lipids that constitute and/or reside within the ER);
x) the expansion of the Golgi (e.g., the number and size of the Golgi, the Golgi
surface, or the number or amounts of proteins and molecules that reside within the
Golgi);
xi) the amount of secretory vesicles or the formation of secretory vesicles;
xii) the amount or rate of secretion of the product;
xiii) the proliferation capacity, e.g., the proliferation rate;
xiv) culture viability or cell survival;
xv) activation of membrane receptors;
xvi) the unfolded protein response (UPR);
xvii) the yield or rate of production of the product;
xviii) the product quality (e.g., aggregation, glycosylation heterogeneity, fragmentation,
proper folding or assembly, post-translational modification, or disulfide bond
scrambling); and /or
xix) cell growth/proliferation or cell specific growth rate.
In any of the methods or cells, e.g., engineered cells, described herein, the cell expresses
or comprises the LMM is selected from a group consisting of SREBF1, SREBF2, SCD1, SCD2,
SCD3, SCD4, and SCD5, or a functional fragment thereof.
In any of the methods or cells, e.g., engineered cells, described herein, the cell expresses
or comprises a product, e.g., a recombinant product, e.g., a next generation biologic selected
from a group consisting of a bispecific antibody, a fusion protein, or a glycosylated protein.
In any of the methods or cells, e.g., engineered cells described herein, the cell is a CHO
cell selected from the group consisting of CHO-K1, CHOKISV, Potelligent CHOKISV (FUT8-
KO), CHO GS-KO, Exceed (CHOKISV GS-KO), CHO-S, CHO DG44, CHO DXBl 1, CHOZN,
or a CHO-derived cell.
Compositions and Preparations
In one aspect, the present disclosure also features a preparation of a product described
herein made by a method described herein. In one embodiment, at least 70, 80, 90, 95, 98 or 99
%, by weight or number, of the products in the preparation are properly folded or assembled. In
one embodiment, less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, or 5%, by weight or number,
of the products in the preparation are aggregated. In one embodiment, less than 50%, 40%, 30%,
25%, 20%, 15%, 10%, or 5%, by weight or number, of the products in the preparation are
fragments of the product.
In some embodiments, the present disclosure features a preparation of a polypeptide, e.g.,
a polypeptide of Table 2 or Table 3, made by a method described herein. In some embodiments,
the cell used in the method is a CHO cell selected from the group consisting of CHOK1 ,
CHOKISV, Potelligent CHOKISV, CHO GS knockout, CHOKISV GS-KO, CHOS, CHO
DG44, CHO DXBl 1, CHOZN, or a CHO-derived cell.
In one aspect, the present disclosure features a mixture comprising a cell described
herein, e.g., a cell comprising a modification that modulates lipid metabolism, and a product
produced by the cell. In one embodiment, the mixture comprises the product at a higher
concentration, e.g., at least, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, or 30% higher
concentration, by weight or number, of product than would be seen without the modification. In
one embodiment, at least 70%, 80%, 90%, 95%, 98 %or 99%, by weight or number, of the
products in the mixture are properly folded or assembled. In one embodiment, less than 50%,
40%, 30%, 25%, 20%, 15%, 10%, or 5%, by weight or number, of the products in the mixture
are aggregated. In one embodiment, less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, or 5%, by
weight or number, of the products in the mixture are fragments of the product. In some
embodiments, the product is a recombinant polypeptide, e.g., a recombinant polypeptide of Table
2 or Table 3.
In one aspect, the present disclosure features a preparation of medium conditioned by
culture of a cell described herein, wherein the cell comprises a modification that modulates lipid
metabolism. In one embodiment, the product is present in the preparation at a higher
concentration, e.g., at least, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, or 30% higher
concentration, by weight or number, than would be seen without the modification. In one
embodiment, at least 70%, 80%, 90%, 95%, 98% or 99 %, by weight or number, of the product
in the preparation are properly folded or assembled. In one embodiment, less than 50%, 40%,
30%, 25%, 20%, 15%, 10%, or 5%, by weight or number, of the products in the preparation are
aggregated. In one embodiment, less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, or 5%, by
weight or number, of the products in the preparation are fragments of the product. In some
embodiments, the product is a recombinant polypeptide, e.g., a recombinant polypeptide of Table
2 or Table 3.
Unless otherwise defined, all technical and scientific terms used herein have the same
meaning as commonly understood by one of ordinary skill in the art to which this invention
belongs. Although methods and materials similar or equivalent to those described herein can be
used in the practice or testing of the present invention, suitable methods and materials are
described below. All publications, patent applications, patents, and other references mentioned
herein are incorporated by reference in their entirety. In addition, the materials, methods, and
examples are illustrative only and are not intended to be limiting. Headings, sub-headings or
numbered or lettered elements, e.g., (a), (b), (i) etc., are presented merely for ease of reading.
The use of headings or numbered or lettered elements in this document does not require the steps
or elements be performed in alphabetical order or that the steps or elements are necessarily
discrete from one another. Other features, objects, and advantages of the invention will be
apparent from the description and drawings, and from the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a series of immunofluorescent images obtained of Flp-In CHO engineered cell
pools, separately transfected with either a control expression vector (Ctrl), or ones encoding
SCDl fused at its C-terminus to a V5 epitope tag (SCD1-V5) or SREBFl fused at its C-terminus
to a V5 epitope tag (SREBFl -V5). The pools were imaged with an anti-V5 primary antibody
and a secondary anti-mouse FITC antibody (middle images) as well as DAPI (left images) and
an overlay of both the left and middle images (right hand column) is shown. Images were
generated using a Leica Confocal Microscope.
Figure 2 shows a series of immunofluorescent images obtained of CHOK1SV glutamine
synthetase knock-out (GS-KO) cell pools, transfected with either a control expression vector
(Ctrl), or ones encoding SCD1-V5 or SREBFl -V5. The pools were imaged with an anti-V5
primary and anti-mouse secondary TRTTC antibody (middle images) as well as DAPI (left
images) and an overlay of both the left and middle images (right hand column) is also shown.
Images were generated using a Leica Confocal Microscope.
Figures 3A, 3B, and 3C show the determination of exogenous SCD1-V5 and SREBFl -
V5 expressed in CHO Flp-In™ cell pools following transient transfection with a plasmid
encoding a difficult to express recombinant Fc fusion protein (also referred to as Fc fusion
protein or FP) (Fig. 3A) or eGFP (Fig. 3B). Fig 3C shows determination of exogenous V5-
tagged SCDl and SREBFl expressed in untransfected stably expressing CHO Flp-In™ cell
pools. Western blot analysis was performed on cell lysates obtained 96 hours following
electroporation with the Fc fusion protein, as well as the cell pool solely expressing the indicated
V5-tagged lipid metabolism modulator (LMM), SCDl or SREBFl . Anti-V5 primary antibody
and anti-mouse HRP conjugated secondary antibody was used to detect expression of the V5-
tagged LMM and anti- -actin or anti L7a (as indicated) followed by exposure with anti-mouse
and anti-rabbit HRP conjugated secondary antibodies respectively were used as loading controls
for LMM detection.
Figure 4 shows the viable cell concentration, as determined using a ViCell cell counter,
of the CHO Flp-In cell pools engineered to stably overexpress the LMM SCD1-V5 and
SREBF1-V5 post transfection with eGFP-containing construct JB3.3 (n=2).
Figures 5A and 5B show the cell culture concentration and culture viability at 24, 48, 72,
and 96 hours after transfection of control, SCD1-V5, SREBF1-V5 and SREBF410-V5 over-
expressing CHOK1 SV GS-KO cell pools with an eGFP containing plasmid. Figure 5A shows
cell concentration. The lower columns represent viable cell concentration whilst the whole
column represents the total concentration of cells; lower error bars represent the standard
deviation of viable cells whilst upper error bars represent that of the total cell concentration.
Figure 5B shows culture viability based on the data outlined in Fig. 5A. Error bars represent
standard deviation. Statistical significance was calculated using two-tailed T-test compared to the
control values of the particular time points: *Viable cell concentration significance using two-
tailed T-test [p<0.05]. +Total cell concentration significance using two-tailed T-tests \p<0.05]
(n=3).
Figures 6A, 6B and 6C show flow cytometry generated data using a FACSCalibur
instrument (BD Biosciences). Median (Fig. 6A), geometric mean (Fig. 6B) and arithmetic mean
(Fig. 6C) values were acquired at 24, 48, 72 and 96 hours post transfection with an eGFP
containing plasmid where samples were taken from control, SCD1-V5 or SREBF1-V5
overexpressing Flp-In CHO cell pools (n=2).
Figures 7A, 7B and 7C show flow cytometry generated data using a FACSCalibur
instrument (BD Biosciences). Median (Fig. 7A), geometric mean (Fig. 7B) values were acquired
at 24, 48, 72 and 96 hours post transfection with an eGFP containing plasmid where samples
were taken from control, SCD1-V5, SREBF1-V5 or SREBF410-V5 overexpressing CHOK1SV
GS-KO derived cells. Figure 7C shows the total fluorescence per ml of culture as calculated by
multiplying the measured arithmetic mean fluorescence by total cell concentration (xl0 6/ml).
Error bars indicate standard deviation. Statistical significance was calculated using a two-tailed
T-test compared to the control values of the particular time points (n=3). ^Indicates statistically
significant values [p<0.05]. Data was generated using FACSCalibur (BD Biosciences).
Figures 8A and 8B show antibody A production in CHO Flp-In cells stably
overexpressing SCD1-V5 and SREBF1-V5 after transient transfection of a nucleic acid construct
encoding antibody A heavy and light chains. Fig. 8A is a western blot showing bands
corresponding to antibody A, as detected by using an anti-heavy chain primary antibody and an
anti-rabbit HRP conjugated secondary antibody. Fig. 8B shows the average fold change in
antibody production in the LMM engineered cell pools compared to values generated from the
control cell pool as determined by Protein A HPLC.
Figures 9A and 9B show the production of an Fc fusion protein in CHO Flp-In cell pools
stably overexpressing SCD 1-V5 and SREBF 1-V5 after transient trans fection of a nucleic acid
construct encoding the fusion protein. Fig. 9A is a western blot showing the bands
representative of the Fc fusion protein as detected by using an anti-heavy chain primary antibody
and an anti-rabbit HRP conjugated secondary antibody. Fig. 9B shows the average fold change
in the Fc fusion protein production in the LMM engineered cell pools compared to values
generated from the control cell pool as determined by Protein A HPLC.
Figures 10A and 10B show the production of a well expressed antibody A in CHO
GSKO cell pools stably overexpressing SCD1-V5, SREBF 1-V5 and SREBF410-V5 after
transient transfection of a nucleic acid construct encoding antibody A heavy and light chains at
48, 72 and 96 h post transfection and in a control, Null CHOK1 SV GS-KO cell pool (a control
pool of cells generated using an empty plasmid to express selection GS gene only, no LMM
agents). Fig. 1OA is a western blot showing the bands representative of antibody A as detected by
using an anti-heavy chain primary antibody and an anti-rabbit HRP conjugated secondary
antibody. Fig. 10B shows the average fold change in antibody production in the LMM
engineered cell pools compared to values generated in the control cell pool as determined by
Protein A HPLC.
Figures 11A and 1IB shows the relative production of a difficult to express Fc fusion
protein in CHOK1SV GS-KO cell pools stably overexpressing SCD1-V5 and SREBF 1-V5 or in
a control cell pool after transient transfection of a nucleic acid construct encoding the Fc fusion
protein. Fig. 11A shows a western blot of the transiently produced fusion protein, as detected by
using an anti-heavy chain primary antibody followed by exposure with an anti-rabbit HRP
conjugated secondary antibody. Fig. 1IB shows the average fold change in the Fc fusion protein
production in the LMM engineered cell pool compared to the control cell pools as determined by
Protein A HPLC.
Figures 12A and 12B show the analysis of antibody A production from supernatant
harvested after 48 and 72 hours from a CHO cell line stably expressing antibody A which have
been transiently transfected with plasmid constructs containing either control (empty), SCD1-V5,
SREBF1-V5 or SREBF410-V5 genes. Fig. 12A shows a western blot of the supernatants from
the cells; antibody A was detected by using an anti-heavy chain primary antibody followed by
exposure with an anti-rabbit HRP conjugated secondary antibody. Figure 12B shows Coomassie
analysis in which the bands show the relative levels of antibody A present in the supernatant at
168 hours post transfection.
Figure 13 shows analysis of antibody A production from supernatant harvested after 48,
72, 96 and 144 hours from a CHO cell line stably expressing antibody A which had been
transiently transfected with plasmid constructs containing either control (empty), SCD1-V5,
SREBF 1-V5 or SREBF4 10-V5 genes where protein A Octet analysis was used to determine
volumetric antibody concentration (n=2).
Figure 14 shows analysis of an FC fusion protein from supernatant samples harvested
after 48, 72, 96 and 144 hours from a CHO cell line stably expressing antibody A which had
been transiently transfected with plasmid constructs containing either control (empty), SCD1-V5,
SREBF 1-V5 or SREBF410-V5 genes where viable cell number and protein A titre
measurements were used to determine specific productivity of the FC fusion protein Error bars
show standard deviation (n=3).
Figure 15A and 15B shows analysis of antibody A production from supernatant samples
harvested after 48, 72, 96 and 144 hours from CHO cell pools stably integrated with control,
SCD1-V5 or SREBF 1-V5 containing vectors and subsequently stably integrated with an
antibody A construct. Figure 15A shows volumetric antibody concentration whilst Figure 15B
shows specific productivity of antibody A. Error bars show standard deviation (n=3).
Figure 16A and 16B shows analysis of FC fusion protein production from supernatant
samples harvested after 48, 72, 96 and 144 hours from a CHO cell pools stably integrated with
control, SCD1-V5, SREBF 1-V5 or SREBF410-V5 containing vectors and subsequently stably
integrated with an FC fusion protein construct. Figure 16A shows volumetric FC fusion protein
concentration whilst Figure 16B shows specific productivity of the FC fusion protein. Error bars
show standard deviation (n=3).
Figures 17A shows western analysis of immunocytokine expression from CHO GSKO
cells following transient transfection of a nucleic acid construct encoding genes appropriate for
expression of the immunocytokine and either no LMM (control), SCD1 , SREBF 1 or SREB41 1
genes at 48 and 96 h post transfection. Supernatant samples were reduced and bands present
detected using an anti heavy chain primary antibody followed by exposure to an anti-rabbit HRP
conjugated secondary antibody. The lower band represents a native heavy chain antibody whilst
the upper band is indicative of a heavy chain molecule fused to a cytokine. Figure 17B shows
relative immunocytokine abundance of samples obtained at 96 hours post transfection.
DETAILED DESCRIPTION
As both current and next generation biologies continue to gain therapeutic utility in
patients, the demand for large quantities of next generation biologic products having a high grade
of quality for therapeutic use, as well as efficient means for production and efficient
development of production cell line will escalate. Furthermore, many next generation biologies
are difficult to express and produce in conventional cell lines using conventional expression
techniques known in the art. The current methods are not sufficient to produce these products in
the large quantities and at the high grade of quality required for clinical use. As such, the present
disclosure features methods and compositions for obtaining higher yields of a product, e.g., a
next generation biologies, with improved quality as compared to the yield and quality obtained
from current production methods. The methods and compositions described herein are also
useful for engineering cells or cell lines with improved productivity, product quality, robustness,
and/or culture viability, as compared to the cell expression systems currently used to produce
recombinant products.
DEFINITIONS
Unless defined otherwise, all technical and scientific terms used herein have the same
meaning as commonly understood by one of ordinary skill in the art to which the invention
pertains. Although any methods and materials similar or equivalent to those described herein can
be used in the practice of and/or for the testing of the present invention, the preferred materials
and methods are described herein. In describing and claiming the present invention, the
following terminology will be used according to how it is defined, where a definition is
provided.
It is also to be understood that the terminology used herein is for the purpose of
describing particular embodiments only, and is not intended to be limiting.
The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at
least one) of the grammatical object of the article. By way of example, "a cell" can mean one cell
or more than one cell.
"Component of a lipid metabolism pathway", as used herein, refers to a molecule,
polypeptide, or enzyme that, directly or indirectly, synthesizes a lipid, degrades a lipid, converts
a lipid from one lipid species to another lipid species, or modifies a lipid. In one embodiment,
the component can be an enzyme substrate, an enzyme reaction product, or an enzyme cofactor.
In one embodiment, the component of a lipid metabolism pathway is a LMM. In one
embodiment, the component of a lipid metabolism pathway is provided in Table 1.
"Endogenous", as used herein, refers to any material from or naturally produced inside an
organism, cell, tissue or system.
"Exogenous", as used herein, refers to any material introduced to or produced outside of
an organism, cell, tissue or system. Accordingly, "exogenous nucleic acid" refers to a nucleic
acid that is introduced to or produced outside of an organism, cell, tissue or system. In an
embodiment, sequences of the exogenous nucleic acid are not naturally produced, or cannot be
naturally found, inside the organism, cell, tissue, or system that the exogenous nucleic acid is
introduced into. In embodiments, non-naturally occurring products, or products containing
portions that are non-naturally occurring are exogenous materials with respect to the host cells
described herein.
"Forming", as used herein, refers to introducing into the cell, synthesizing within the cell,
or any other process that results in the nucleic acid encoding a LMM or an exogenous LMM
being located within the cell.
"Heterologous", as used herein, refers to any material from one species, when introduced
to an organism, cell, tissue or system from a different species. In embodiments, a heterologous
material also encompasses a material that includes portions from one or multiple species or
portions that are non-naturally occurring. By way of example, in an embodiment, a nucleic acid
encoding a fusion protein wherein a portion of the fusion protein is human, a portion of the
fusion protein is bacteria, and a portion of the fusion protein is non-naturally occurring, and the
nucleic acid is introduced to a human cell, the nucleic acid is a heterologous nucleic acid.
"Lipid metabolism pathway", as used herein, refers to a process associated with the
synthesis of a lipid or lipid-associated molecule, the elongation of a lipid or lipid-associated
molecule, the degradation of a lipid or lipid-associated molecule, the incorporation of a lipid or
lipid-associated molecule into a membrane, the state of saturation of a lipid or lipid-associated
molecule (e.g., saturated or unsaturated), or conversion or modification of the chemical structure
(e.g., re-esterification) of a lipid or lipid-associated molecule. In one embodiment, the lipid
metabolism pathway results in lipid synthesis, lipid elongation, lipid degradation, changes in
membrane composition or fluidity, formation or modulation of lipid rafts, or modification or
conversion of a lipid (e.g., saturation or de-saturation of a lipid, or re-esterification of a lipid).
Examples of lipid metabolism pathways include, but are not limited to: de novo lipogenesis, fatty
acid re-esterification, fatty acid saturation, fatty acid de-saturation, fatty acid elongation, and
phospholipid biosynthesis, and unfolded protein response.
"Lipid metabolism modulator" or "LMM", as used herein, refers to a molecule, gene
product, polypeptide, or enzyme that modulates, e.g., increases or decreases, one or more of the
following: the expression (e.g., transcription or translation) of a component involved in a lipid
metabolism pathway; the activity (e.g., enzymatic activity) of a component, e.g., gene product,
involved in a lipid metabolism pathway; the level or amount of lipids present in a cell; the level
or amount of lipid rafts or rate of lipid raft formation; the fluidity, permeability, or thickness of a
cell membrane, e.g., plasma membrane or an organelle membrane; the conversion of saturated
lipids to unsaturated lipids or vice versa; the level or amount of saturated lipids or unsaturated
lipids in a cell, e.g., monounsaturated lipids; lipid composition to achieve a favorable lipid
composition that has a favorable impact on the activity of the ER; the expansion of the ER; the
expansion of the Golgi; the level or amount of secretory vesicles or secretory vesicle formation;
the level or rate of secretion; activation or inactivation of membrane receptors (e.g., ATR (see
e.g., The increase of cell-membranous phosphatidylcholines containing polyunsaturated fatty
acid residues induces phosphorylation of p53 through activation of ATR. Zhang XH, Zhao C,
Ma ZA. J Cell Sci. 2007 Dec l;120(Pt 23):4134-43 PMID: 18032786; ATR (ataxia telangiectasia
mutated- and Rad3 -related kinase) is activated by mild hypothermia in mammalian cells and
subsequently activates p53. Roobol A, Roobol J, Carden MJ, Bastide A, Willis AE, Dunn WB,
Goodacre R, Smales CM. Biochem J . 201 1 Apr 15;435(2):499-508. doi: 10.1042/BJ20101303.
PMID: 21284603) and SREPB (see e.g., Int J Biol Sci. 2016 Mar 21;12(5):569-79. doi:
10.7150/ijbs. 14027. eCollection 2016. Dysregulation ofthe Low-Density Lipoprotein Receptor
Pathway Is Involved in Lipid Disorder-Mediated Organ Injury. Zhang Y, Ma KL, Ruan XZ, Liu
BC); and additional receptors, see e.g., Biochim Biophys Acta. 2016 Mar 17. pii: S1388-
1981(16)30071-3. doi: 10.1016/j.bbalip.2016.03.019; and/or the unfolded protein response
(UPR) . In one embodiment, the LMM comprises a polypeptide. In one embodiment, the LMM
comprises a transcriptional regulator, e.g., a transcription factor. In one embodiment, the LMM
comprises SREBFl or a functional fragment thereof (e.g., SREBF-410). In one embodiment, the
LMM comprises an enzyme. In one embodiment, the LMM comprises SCD1 or a functional
fragment thereof.
"Modification" as used herein in the expression "modification that modulates lipid
metabolism" refers to an agent that is capable of effecting an increase or decrease in the
expression or activity of a component, e.g., gene product, of a lipid metabolism pathway
described herein. In embodiments, the modification results in increasing the expression or
activity of a component of a lipid metabolism pathway, e.g., a 1%, 2%, 5%, 10%, 15%, 20%,
25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% 95%, 99%, 1-
fold, 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold or more increase in expression or
activity of a component of a lipid metabolism pathway, e.g., as compared to the expression or
activity of the component in the absence of the modification. In embodiments, the modification
results in decreasing the expression or activity of a component of a lipid metabolism pathway,
e.g., a 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%,
75%, 80%, 85%, 90% 95%, 99%%, 1-fold, 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold
or more decrease in expression or activity of a component of a lipid metabolism pathway, e.g., as
compared to the expression or activity of the component in the absence of the modification. In
some embodiments where the expression or activity of a component of the lipid metabolism
pathway is decreased, the component is a negative regulator of a lipid metabolism pathway. In
one embodiment, the modification comprises a heterologous or exogenous nucleic acid sequence
encoding a lipid metabolism modulator. In one embodiment, the modification is an exogenous
lipid metabolism modulator, e.g., small molecule or polypeptide, that can be introduced to a cell,
e.g., by culturing the cell in the presence of the molecule or polypeptide, to modulate the lipid
metabolism of the cell.
The terms "nucleic acid", "polynucleotide", and "nucleic acid molecule", as used
interchangeably herein, refer to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), or a
combination of a DNA or RNA thereof, and polymers thereof in either single-, double-, or triple-
stranded form. The term "nucleic acid" includes, but is not limited to, a gene, cDNA, or an
mRNA. In one embodiment, the nucleic acid molecule is synthetic (e.g., chemically synthesized
or artificial) or recombinant. Unless specifically limited, the term encompasses molecules
containing analogues or derivatives of natural nucleotides that have similar binding properties as
the reference nucleic acid and are metabolized in a manner similar to naturally or non-naturally
occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also
implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon
substitutions), alleles, orthologs, SNPs, and complementary sequences as well as the sequence
explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating
sequences in which the third position of one or more selected (or all) codons is substituted with
mixed-base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991);
Ohtsuka et al, J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al, Mol. Cell. Probes
8:91-98 (1994)).
"Peptide," "polypeptide," and "protein", as used interchangeably herein, refer to a
compound comprised of amino acid residues covalently linked by peptide bonds, or by means
other than peptide bonds. A protein or peptide must contain at least two amino acids, and no
limitation is placed on the maximum number of amino acids that can comprise a protein's or
peptide's sequence. In one embodiment, a protein may comprise of more than one, e.g., two,
three, four, five, or more, polypeptides, in which each polypeptide is associated to another by
either covalent or non-covalent bonds/interactions. Polypeptides include any peptide or protein
comprising two or more amino acids joined to each other by peptide bonds or by means other
than peptide bonds. As used herein, the term refers to both short chains, which also commonly
are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer
chains, which generally are referred to in the art as proteins, of which there are many types.
"Polypeptides" include, for example, biologically active fragments, substantially homologous
polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified
polypeptides, derivatives, analogs, fusion proteins, among others.
"Recombinant product" refers to a product that can be produced by a cell or a cell-free
system. The product can be a molecule, a nucleic acid, a polypeptide, or any hybrid thereof. A
recombinant product is one for at which at least one component of the product or at least one
nucleotide of a sequence which controls the production or expression of the product, was formed
by genetic engineering. Genetic engineering as used herein to generate a recombinant product or
a construct that encodes a recombinant product encompasses recombinant DNA expression
techniques known in the art (e.g., as described in Current Protocols in Molecular Biology); site-
directed, scanning, or random mutagenesis; genome modification strategies employing CRISPR-
based strategies; and zinc finger nuclease (ZFN)-based strategies. By way of example, in
embodiments where the recombinant product is a nucleic acid, at least one nucleotide of the
recombinant nucleic acid, or at least one nucleotide of a sequence that controls the production,
e.g., transcription, of the recombinant nucleic acid was formed by genetic engineering. In one
embodiment, the recombinant product is a recombinant polypeptide. In one embodiment, the
recombinant product is a naturally occurring product. In one embodiment, the recombinant
product is a non-naturally occurring product, e.g., a synthetic product. In one embodiment, a
portion of the recombinant product is naturally occurring, while another portion of the
recombinant product is non-naturally occurring. In another embodiment, a first portion of the
recombinant product is one naturally occurring molecule, while another portion of the
recombinant product is another naturally occurring molecule that is different from the first
portion.
"Recombinant polypeptide" refers to a polypeptide that can be produced by a cell
described herein. A recombinant polypeptide is one for which at least one nucleotide of the
sequence encoding the polypeptide, or at least one nucleotide of a sequence which controls the
expression of the polypeptide, was formed by genetic engineering or manipulation (of the cell or
of a precursor cell). E.g., at least one nucleotide was altered, e.g., it was introduced into the cell
or it is the product of a genetically engineered rearrangement. In an embodiment, the sequence
of a recombinant polypeptide does not differ from a naturally or non-naturally occurring isoform
of the polypeptide or protein. In an embodiment, the amino acid sequence of the recombinant
polypeptide differs from the sequence of a naturally occurring or a non-naturally isoform of the
polypeptide or protein. In an embodiment, the recombinant polypeptide and the cell are from the
same species. In an embodiment, the amino acid sequence of the recombinant polypeptide is
the same as or is substantially the same as, or differs by no more than 1%, 2%, 3%, 4%, 5%,
10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,
90%, 95%, or 99% from, a polypeptide encoded by the endogenous genome of the cell. In an
embodiment, the recombinant polypeptide and the cell are from the same species, e.g., the
recombinant polypeptide is a human polypeptide and the cell is a human cell. In an embodiment,
the recombinant polypeptide and the cell are from different species, e.g., the recombinant
polypeptide is a human polypeptide and the cell is a non-human, e.g., a rodent, e.g., a CHO,
other mammalian cell, an insect cell, a plant cell, a fungal cell, a viral cell, or a bacterial cell. In
an embodiment, the recombinant polypeptide is exogenous to the cell, in other words, the cell is
from a first species and the recombinant polypeptide is from a second species. In one
embodiment, the polypeptide is a synthetic polypeptide. In one embodiment, the polypeptide is
derived from a non-naturally occurring source. In an embodiment, the recombinant polypeptide
is a human polypeptide or protein which does not differ in amino acid sequence from a naturally
or non-naturally occurring isoform of the human polypeptide or protein. In an embodiment, the
recombinant polypeptide differs from a naturally or non-naturally occurring isoform of the
human polypeptide or protein at no more than 1, 2, 3, 4, 5, 10, 15 or 20 amino acid residues. In
an embodiment, the recombinant polypeptide differs from a naturally occurring isoform of the
human polypeptide at no more than 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, or 15% of its
amino acid residues. In embodiments where a portion of the recombinant polypeptide
comprises a sequence derived from a portion of a naturally or non-naturally occurring isoform of
a human polypeptide, the portion of the recombinant polypeptide differs from the corresponding
portion of the naturally or non-naturally occurring isoform by no more than 1, 2, 3, 4, 5, 10, 15,
or 20 amino acid residues, or 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, or 15% of its amino
acid residues.
"Homologous", "identity", or "similarity" as used herein refers to the subunit sequence
identity between two polymeric molecules, e.g., between two nucleic acid molecules, such as,
two DNA molecules or two RNA molecules, or between two polypeptide molecules. When a
subunit position in both of the two molecules is occupied by the same monomeric subunit; e.g., if
a position in each of two DNA molecules is occupied by adenine, then they are homologous or
identical at that position. The homology between two sequences is a direct function of the
number of matching or homologous positions; e.g., if half (e.g., five positions in a polymer ten
subunits in length) of the positions in two sequences are homologous, the two sequences are 50%
homologous; if 90% of the positions (e.g., 9 of 10), are matched or homologous, the two
sequences are 90% homologous.
The term "next generation biologic" or "NGB" as used herein refers to a biological
composition comprising a cell or a composition produced by a cell. The biological composition
is selected from the group consisting of a composition with at least one natural component, a
composition with at least one natural component and at least one non-natural component, a
composition with at least one natural component and at least one natural structure, and a
composition with at least one natural component and at least one non-natural structure, or any
combinations thereof. Next generation biologies often comprise complex and/or non-natural
structures. Examples of next generation biologies include, but are not limited to, fusion proteins,
enzymes or recombinant enzymes, proteins or recombinant proteins, recombinant factors with
extended half-lives, growth hormones with long acting therapies, multimeric glycoproteins, next
generation antibodies, antibody fragments, or antibody-like proteins (ALPs), vesicles, exosomes,
liposomes, viruses, and virus-like particles, mucins, nanoparticles, extracts of a cell, and a cell
being used as a reagent.
The disclosures of each and every patent, patent application, and publication cited herein
are hereby incorporated herein by reference in their entirety. While this invention has been
disclosed with reference to specific aspects, it is apparent that other aspects and variations of this
invention may be devised by others skilled in the art without departing from the true spirit and
scope of the invention. The appended claims are intended to be construed to include all such
aspects and equivalent variations.
MODULATION OF LIPID METABOLISM
The present disclosure features methods and compositions for modulating lipid
metabolism in a cell or a cell-free system, for example, by introducing a modification to the cell
or cell-free system that results in the modulation of lipid metabolism. In embodiments, the
present disclosure features the use of global regulators that impact multiple aspects of pathways
or processes involved in lipid metabolism, e.g., the de novo lipogenesis, fatty acid re-
esterification, fatty acid saturation or desaturation, fatty acid elongation, and phospholipid
biosynthesis pathways. By way of example, the global regulator is upstream in one or more lipid
metabolism pathways or processes such that the global regulator impacts several, e.g., two or
more, downstream processes or downstream components of lipid metabolism. In one
embodiment, the global regulator is a transcription factor that can activate the expression of more
than one, e.g., two or more, target genes involved in different lipid metabolism processes or
pathways. Accordingly, without wishing to be bound by any theory, the use of a global regulator
as described herein can result in a greater increase in production capacity, robustness, and
survival of the cell than compared to the use of a downstream effector that modulates only a
single target or other component of lipid metabolism. While not wishing to be bound by any
theory, it is believed that a global or more widespread modulation of multiple lipid metabolism
pathways increases the production capacity of a cell by affecting more processes involved in
improving production capacity, product quality, and robustness of the cell.
Lipid metabolism pathways as described herein refer to processes that relate to the
synthesis, degradation, conversion, or modification of lipids or lipid-associated molecules. Lipid
molecules include, but are not limited to, fatty acids, glycerolipids, glycerophospholipids,
phospholipids, saccharolipids, sphingolipids, and sterol lipids, e.g., cholesterol, and polyketides.
Examples of lipid metabolism pathways include, but are not limited to: de novo lipogenesis, fatty
acid re-esterification, fatty acid saturation, fatty acid de-saturation, fatty acid elongation, and
phospholipid biosynthesis. In one embodiment, the methods described herein provide a cell
comprising a modification that modulates lipid metabolism. The modification that modulates
lipid metabolism can be an agent that increases or decreases the expression of a component
involved in lipid metabolism. In one embodiment, the modification that modulates lipid
metabolism comprises an exogenous nucleic acid encoding a lipid metabolism modulator
(LMM). In such embodiments, the exogenous nucleic acid encoding a LMM is introduced to the
cell by any of the nucleic acid delivery methods or techniques described herein, e.g., transduction
or transfection
In one embodiment, the methods described herein provide a cell comprising one or more,
e.g., one, two, three, four, five, six, seven, eight, nine or ten, modifications that modulate lipid
metabolism. In embodiments where the cell comprises two or more modifications that modulate
lipid metabolism, each modification that modulates lipid metabolism comprises an exogenous
nucleic acid that encodes a LMM. In one embodiment, each of the two or more exogenous
nucleic acids that encode a LMM can be located within the same nucleic acid molecule, or are
placed on two or more different nucleic acid molecules. In such embodiments where the cell
comprises two or more nucleic acid sequences encoding LMMs, the LMMs are different from
each other, e.g., encode a different polypeptide sequence or have a different function.
In embodiments, modulation of lipid metabolism in a cell, e.g., by introducing and
expressing an exogenous nucleic acid encoding an LMM described herein, alters, e.g., increases
or decreases, one or more of the following:
i) the expression (e.g., transcription and/or translation) of a component involved in a
lipid metabolism pathway;
ii) the activity (e.g., enzymatic activity) of a component involved in a lipid
metabolism pathway;
iii) the amount of lipids (e.g., phospholipids, or cholesterol) present in a cell;
iv) the amount of lipid rafts or rate of lipid raft formation;
v) the fluidity, permeability, and/or thickness of a cell membrane (e.g., a plasma
membrane, a vesicle membrane, or an organelle membrane);
vi) the conversion of saturated lipids to unsaturated lipids or conversion of
unsaturated lipids to saturated lipids;
vii) the amount of saturated lipids or unsaturated lipids, e.g., monounsaturated lipids;
viii) the composition of lipids in the cell to attain a favorable composition that
increases ER activity;
ix) the expansion of the ER (e.g., size of the ER, the ER membrane surface, or the
amounts of the proteins and lipids that constitute and/or reside within the ER);
x) the expansion of the Golgi (e.g., the number and size of the Golgi, the Golgi
surface, or the number or amounts of proteins and molecules that reside within the
Golgi);
xi) the amount of secretory vesicles or the formation of secretory vesicles;
xii) the amount or rate of secretion of the product;
xiii) the proliferation capacity, e.g., the proliferation rate;
xiv) culture viability or cell survival;
xv) activation of membrane receptors;
xvi) the unfolded protein response (UPR);
xvii) the yield or rate of production of the product;
xviii) the product quality (e.g., aggregation, glycosylation heterogeneity, fragmentation,
proper folding or assembly, post-translational modification, or disulfide bond
scrambling); and /or
xix) cell growth/proliferation or cell specific growth rate.
In an embodiment, modulation of lipid metabolism results in an increase in any of the
properties listed above, e.g., a 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%,
95%, or 99%, or more, or at least 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold,
or 100-fold or more, increase in any of the properties listed above as compared to a cell without
modulation of lipid metabolism. In an embodiment, modulation of lipid metabolism results in a
decrease in any of the properties listed above, e.g., a 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%,
60%, 70%, 80%, 90%, 95%, or 99%, or more, or at least 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-
fold, 20-fold, 50-fold, or 100-fold or more, decrease in any of the properties listed above as
compared to a cell without modulation of lipid metabolism.
In an embodiment, a modification that modulates lipid metabolism increases or decreases
the expression or activity of a component involved in one or more lipid metabolism pathways.
In embodiments where the modification that modulates lipid metabolism results in an increase in
the expression, e.g., transcription or translation, or an increase in the activity of a component of a
lipid metabolism pathway, the component is a positive regulator of the lipid metabolism
pathway. In embodiments where the modification that modulates lipid metabolism results in a
decrease in the expression, e.g., transcription or translation, or a decrease in the activity of a
component of a lipid metabolism pathway, the component is a negative regulator of the lipid
metabolism pathway. Assays for quantifying the expression, e.g., transcription and/or
translation, of a gene of the lipid metabolism pathway, are known in the art, and include
quantifying the amount of mRNA encoding the gene; or quantifying the amount of the gene
product, or polypeptide; PCR-based assays, e.g., quantitative real-time PCR; Northern blot; or
microarray. Assays for quantifying the activity of a component of the lipid metabolism pathway,
e.g., an enzyme of the lipid metabolism pathway, will be specific to the particular component of
the lipid metabolism pathway.
In embodiments where the modulation of the lipid metabolism of a cell results in an
increase in the level or amount of lipids in the cell, the total level or total amount of lipids in the
cell can be increased. In another embodiment, the level or amount of one or more species of
lipids, e.g., a phospholipid or cholesterol, in the cell can be increased. An increase in the level or
amount of lipids in the cell (e.g., total or a select lipid species) comprises a 1%, 2%, 5%, 10%,
15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,
95%, or more, or a one-fold, two-fold, three-fold, four- fold, or five-fold, 10-fold, 20-fold, 50-
fold, or 100-fold, increase in the level or amount of lipids in the cell after modulation of lipid
metabolism, e.g., live cells, as compared to cells that do not comprise a modification that
modulates lipid metabolism. Assays for quantifying the level or amount of lipids in a cell are
known in the art, and include enzymatic assays and oxidation assays and measurement by mass
spectrometry of lipid components in a particular compartment (e.g., organelle) or from the total
cell.
In one embodiment, a modification that modulates lipid metabolism results in increased
cell survival. For example, cell survival can be measured by determining or quantifying cell
apoptosis, e.g., the number or amount of cells that have been killed or died. An increase in cell
survival comprises a 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%,
60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, or a one-fold, two-fold, three-fold, four
fold, or five-fold, 10-fold, 20-fold, 50-fold, or 100-fold„ increase in the number of cells after
modulation of lipid metabolism, e.g., live cells, as compared to cells that do not comprise a
modification that modulates lipid metabolism. Alternatively, an increase in cell survival
comprises a 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%,
70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more decrease in the number of apoptotic cells
after modulation of lipid metabolism, e.g., as compared to cells without modulation of lipid
metabolism. Methods for detecting cell survival or apoptosis are known in the art, e.g., Annexin
V assays, and are described herein in the Examples.
In one embodiment, a modification that modulates lipid metabolism results in increased
culture viability. For example, culture viability can be measured by determining or quantifying
the number or amount of live cells, e.g., live cells in a culture or population of cells, or cells that
have a characteristic related to being viable, e.g., proliferation markers, intact DNA, or do not
display apoptotic markers. An increase in culture viability comprises a 1%, 2%, 5%, 10%, 15%,
20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or
more, or a one-fold, two-fold, three-fold, four-fold, or five-fold, 10-fold, 20-fold, 50-fold, or
100-fold, or more increase in the number of cells, e.g., live cells, after modulation of lipid
metabolism, e.g., as compared to cells without modulation of lipid metabolism. Methods for
determining culture viability are known in the art, and are described herein in Example 3. Other
methods for assessing culture viability include, but are not limited to, trypan blue exclusion
methods followed by counting using a hemocytometer or Vi-CELL (Beckman-Coulter). Other
methods for determining viable biomass include methods using radiofrequency impedance or
capacitance (e.g., Carvell and Dowd, 2006, Cytotechnology, 50:35-48), or using Raman
spectroscopy (e.g., Moretto et al., 201 1, American Pharmaceutical Review, Vol. 14).
In one embodiment, a modification that modulates lipid metabolism results in increased
cell proliferation. For example, the ability of a cell to proliferate can be measured by
quantifying or counting the number of cells, cell doublings, or growth rate of the cells.
Alternatively, proliferating cells can be identified by analysis of the genomic content of the cells
(e.g., replicating DNA), e.g., by flow cytometry analysis, or presence of proliferation markers,
e.g., Ki67, phosphorylated cyclin-CDK complexes involved in cell cycle. An increase in the
ability to proliferate comprises a 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%,
50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, or one-fold, two
fold, three-fold, four-fold, five-fold, 10-fold, 20-fold, 50-fold, or 100-fold, or more increase in
the number of cells, or number of cells expressing a proliferation marker, after modulation of
lipid metabolism. Alternatively, an increase in the ability to proliferate comprises a 1%, 2%, 5%,
10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,
90%, 95%, 98%, 99%, or more, or one-fold, two-fold, three-fold, four-fold, five-fold, 10-fold,
20-fold, 50-fold, or 100-fold, or more increase in the doubling or growth rate of the cells after
modulation of lipid metabolism. Cell counting can be performed using a cell counting machine,
or by use of a hemacytometer.
In one embodiment, a modification that modulates lipid metabolism results in an increase
in production capacity, e.g., the amount, quantity, or yield of product produced, or the rate of
production. An increase in the amount, quantity, or yield of the product produced comprises 1%,
2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, 98%, 99%, or more, or by 1-fold, 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-
fold or more increase in the amount, quantity, or yield of the product produced after modulation
of lipid metabolism, e.g., as compared to the amount, quantity, or yield of the product produced
by a cell without modulation of the lipid metabolism. An increase in the rate of production
comprises 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%,
70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, or byl-fold, 2-fold, 5-fold, 10-fold, 20-
fold, 50-fold, 100-fold, or more increase in the amount, quantity, or yield of the product
produced after modulation of lipid metabolism, after modulation of lipid metabolism, e.g., as
compared to the rate of production of a cell without modulation of the lipid metabolism. In one
embodiment, the rate of production is determined by determining the amount, quantity, or yield
of the product produced in a specific unit of time.
In one embodiment, a modification that modulates lipid metabolism results in an increase
in the quality of the product, e.g., aggregation, glycosylation status or heterogeneity,
fragmentation, proper folding or assembly, post-translational modification, or disulfide bond
scrambling. An increase quality of the product comprises a 1%, 2%, 5%, 10%, 15%, 20%, 25%,
30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or
more, or by 1-fold, 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold or more of: an increase in
the amount or quantity of non-aggregated product, an increase in the ratio of non-aggregated
product to aggregated product, or decrease in the amount or quantity of aggregated product, after
modulation of lipid metabolism e.g., as compared to that observed in a cell without modulation
of the lipid metabolism. An increase quality of the product comprises a 1%, 2%, 5%, 10%, 15%,
20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%,
98%, 99%, or more, or by 1-fold, 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold or more of:
an increase in the amount or quantity of properly folded or assembled product, an increase in the
ratio of properly folded or assembled product to misfolded, unfolded, partially assembled, or
non-assembled product, or decrease in the amount or quantity of misfolded, unfolded, partially
assembled, or non-assembled product, after modulation of lipid metabolism e.g., as compared to
that observed in a cell without modulation of the lipid metabolism. An increase quality of the
product comprises a 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%,
60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, or by 1-fold, 2-fold, 5-fold,
10-fold, 20-fold, 50-fold, 100-fold or more of: an increase in the amount or quantity of non-
fragmented or full-length product, or a decrease in the amount or quantity of fragmented product
after modulation of lipid metabolism, e.g., as compared to that observed in a cell without
modulation of the lipid metabolism. An increase quality of the product comprises a 1%, 2%, 5%,
10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,
90%, 95%, 98%, 99%, or more, or by 1-fold, 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold or
more of: an increase in the amount or quantity of functional product, or a decrease in the amount
or quantity of non-functional or dysfunctional product after modulation of lipid metabolism, e.g.,
as compared to that observed in a cell without modulation of the lipid metabolism. An increase
quality of the product comprises a 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%,
50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more, or by 1-fold, 2-
fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold or more of: an increase or decrease in the glycan
heterogeneity after modulation of lipid metabolism, e.g., as compared to that observed in a cell
without modulation of the lipid metabolism. An increase quality of the product comprises a 1%,
2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, 98%, 99%, or more, or by 1-fold, 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-
fold or more of: an increase in the amount or quantity of functional product, or a decrease in the
amount or quantity of non-functional or dysfunctional product after modulation of lipid
metabolism, e.g., as compared to that observed in a cell without modulation of the lipid
metabolism.
LIPID METABOLISM MODULATORS
As described herein, modulation of the lipid metabolism can be achieved by expressing or
introducing a LMM, or by altering the regulation of a LMM. In one embodiment, an LMM is
overexpressed in a cell, e.g., by introducing an exogenous nucleic acid encoding a LMM or by
increasing expression by introducing promoter elements or other regulatory transcriptional
elements. In another embodiment, the expression or activity of an LMM is inhibited or
decreased, e.g., by introducing an inhibitor of the LMM or an exogenous inhibitory nucleic acid,
e.g., an R A interfering agent. Examples of inhibitory nucleic acids include short interfering
R As (siRNAs) and short hairpin R As (shRNAs) that target the LMM, e.g, the mR A
encoding the LMM. In one embodiment, the activity or expression of an LMM is increased or
decreased by altering the post-translational modifications or other endogenous regulatory
mechanisms that regulate LMM activity or expression. Regulation by post-translational
modifications include, but are not limited to, phosphorylation, sumoylation, ubiquitination,
acetylation, methylation, or glycosylation can increase or decrease LMM expression or activity.
By way of example, regulation of post-translational modifications can be achieved through
modulation of the enzyme or molecule that modifies the LMM, or modification of the LMM
such that the post-translational modification cannot occur or occurs more frequently or
constitutively. Regulation of the LMM can also include modulating endogenous regulatory
mechanisms that can increase or decrease LMM expression or activity, e.g., increase or decrease
one or more of: miRNA regulation, protein cleavage, expression of specific isoforms, alternative
splicing, and degradation.
In one embodiment, the LMM modulates, e.g., increases or decreases, the expression, e.g.,
transcription, or activity of a component of the lipid metabolism pathway. In another
embodiment, the LMM modulates, e.g., increases or decreases, the synthesis, degradation,
elongation, or structural conformation (e.g., saturation or desaturation, or esterification) of a lipid
or lipid-associated molecule. Exemplary LMMs and/or components of the lipid metabolism
pathway are listed, but not limited, to those listed in Table 1.
Table 1. Lipid Metabolism Pathways and Components/Gene Products Thereof
KDSR (3-ketosphinganine reductase)
LCS (polypeptide N-acetylgalactosaminyltransferase)







PSS1 (phosphatidylserine synthase 1)
PSS2 (phosphatidylserine synthase 2)





Fatty Acid Desaturation SCD1 (stearoyl CoA desaturase-1)
SCD2 (stearoyl CoA desaturase-2)
SCD3 (stearoyl CoA desaturase-3)
SCD4 (stearoyl CoA desaturase-4)
SCD5 (Steoryl CoA desaturase-5)
PED (plasmanylethanolamine desaturase)
Regulation of SREBF1 and other SIP (site- 1 protease)
pathways S2P (site-2 protease)
SCAP (SREBF cleavage-activating protein)
INSIG1 (insulin induced gene 1)
INSIG2 (insulin induced gene 2)
HMG CoA reductase (2-hydroxy-3-methylgulatryl-CoA
reductase)
PPAR receptors, e.g., PPARa, PPARy
In one embodiment, the LMM comprises at least 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity or homology
with a component, e.g., gene product, involved in a lipid metabolism pathway, e.g., provided in
Table 1; or differs by 1, 2, or 3 or more amino acid residues but no more than 50, 40, 30, 20, 15,
or 10 amino acid residues from the amino acid sequence of a component, e.g., gene product,
involved in the lipid metabolism pathway, e.g., provided in Table 1.
In one embodiment, the LMM comprises a functional fragment of a component involved in
the lipid metabolism pathway, e.g., provided in Table 1. A functional fragment of an LMM as
described herein may comprise one or more functional domains of the LMM. By way of
example, a functional fragment of a LMM that is a transcription factor comprises a DNA binding
domain and a transactivation domain. By way of example, a functional fragment of a LMM that
is an enzyme comprises a domain with enzymatic activity. A functional fragment of an LMM as
described herein retains functional activity, e.g., at least 5%, 10%, 20%, 30%, 40%, 50%, 60%,
70% , 80% , or 90%> of the functional activity, of the full-length LMM. Functional fragments of
an LMM can be experimentally determined by one skilled in the art, or can be predicted using
algorithms based on sequence homology of functional domains. Exemplary LMMs are further
described below.
In any of the embodiments of the methods described herein, the LMM is a transcriptional
regulator. In one embodiment, the LMM is a transcription factor or transcriptional activator, that
binds to the DNA or associates in a complex that binds to DNA, and recruits or associates in a
complex that recruits RNA polymerase for transcription of one or more gene products involved
in lipid metabolism. In one embodiment, the LMM binds to a sterol binding element and/or E-
box promoter sequences. In one embodiment, the LMM comprises sterol regulatory element
binding factor 1 (SREBF1) or sterol regulatory element binding factor 2 (SREBF2) or a
functional fragment or isoform thereof.
In an embodiment, the LMM comprises a global transcriptional activator or transcription
factor. In one embodiment, the LMM is capable of modulating the transcription of two or more,
e.g., two, three, four, five, six, or more, components of a lipid metabolism pathway, e.g., as
provided in Table 1. In another embodiment, the LMM is capable of modulating the
transcription of one or more, e.g., one, two, three, four, or five, or more, components of two or
more lipid metabolism pathways, e.g., components and pathways as provided in Table 1.
Sterol regulatory element binding factor 1 (SREBF1) is a global transcriptional activator
which upregulates the transcription of genes involved in lipogenesis, fatty acid re-esterification,
fatty acid desaturation and elongation, and phospholipid biosynthesis by binding to sterol
regulatory element (SRE) and E-box promoter sequences (Hagen, Rodriguez-Cuenca et al.
2010) present in the promoter regions of target genes. Transcription of the SREBF1 gene itself
is endogenously regulated by the presence of the sterol regulatory element (SRE) amongst other
transcriptional regulating elements in the promoter region of the gene. On top of this, a
multitude of posttranslational regulating mechanisms including phosphorylation, ubiquitination,
sumoylation, acetylation, fatty acid-mediated modifications and proteolytic processing make for
a tightly controlled but adaptable homeostatic system fixed around SREBF1 .
Full-length SREBF1 is synthesized and localizes primarily to the endoplasmic reticulum
(ER). Membrane integral SREBFl forms a complex with SREBF cleavage-activating protein
(SCAP) which can facilitate migration of SREBFl to the Golgi. However, when high
sterol levels (particularly cholesterol) are present, a conformational change in SCAP is
induced which aids binding to the membrane integral protein insig (insulin induced gene), thus
inhibiting migration of this complex. In the absence of sterols, insig does not bind to SCAP,
therefore allowing COPII mediated vesicle formation, and subsequent migration of the
SREBF:SCAP complex to the Golgi. Sequential proteolytic cleavage occurs in the Golgi
mediated by site-1 protease (SIP) and site-2 protease (S2P) proteins liberating the N-terminal
basic helix loop helix leucine zipper (bHLHlz) of SREBFl which is immediately present in the
cytoplasm, but migrates to the nucleus. Lysine residues present on the cleaved SREBFl are
ubiquitinated and degraded by the 26S proteasome but this ubiquitination can be inhibited
through acetylation of the lysine residues which allows migration to the nucleus. Finally,
nuclear SREBFl can bind to sterol regulatory element (SRE) sequences upstream of a number
of genes responsible for de novo lipogenesis (fatty acid synthase (FAS) and acetyl coA
carboxylase (ACQ), fatty acid re-esterfication (diacylglycerol acyltransferase (DGAT),
glycerol-3 -phosphate (GPAT) and lipoprotein lipase (LPL)), phospholipid biosynthesis
(CTP:phosphocholine cytidylyltransferase (CCT)), fatty acid desaturation (stearoyl-coA
desaturase 1 (SCD1)). Nuclear SREBFl is also capable of activating transcription of the full
length SREBFl gene itself, but this is also dependent on activation of the liver X receptor
(LXR) promoter sequence also located upstream of the gene (Brown, Goldstein 1997-
BROWN, M.S. and GOLDSTEIN, J.L., 1997. The SREBP Pathway: Regulation of Cholesterol
Metabolism by Proteolysis of a Membrane-Bound Transcription Factor. Cell, 89(3), pp. 331-
340) (Hagen, Rodriguez-Cuenca- HAGEN, R.M., RODRIGUEZ-CUENCA, S. and VIDAL-
PUIG, A., 2010. An allostatic control of membrane lipid composition by SREBPl . FEBS
letters, 584(12), pp. 2689-2698).
In one embodiment, the LMM comprises SREBFl, an isoform, or a functional fragment
thereof. The amino acid sequence for SREBFl is provided below:
MDELAFGEAALEQTLAEMCELDTAVLNDIEDMLQL INNQDSDFPGLFDAPYAGGETGDTGPS SPGANS PESFSSASL













LASCYLPPAFLSAPGQRMSMLAEAARTVEKLGDHRLLLDCQQMLLRLGGGTTVTSS (SEQ ID NO: 1 ) .













































ccgtcacttccagctag (SEQ ID NO: 2 ) .
In one embodiment, the LMM comprises at least 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence of
SREBF1 ; e.g., SEQ ID NO: 1; or differs by 1, 2, or 3 or more amino acid residues but no more
than 50, 40, 30, 20, 15, or 10 amino acid residues from the amino acid sequence of SREBF1,
e.g., SEQ ID NO: 1.
Isoforms of SREBF1 are known in the art, and include isoform a and isoform b, as well as
species or cell specific, e.g., CHO cell specific, isoforms, such as isoform c . The amino acid

















LLASCYLPPGFLSAPGQRVGMLAEAARTLEKLGDRRLLHDCQQMLMRLGGGTTVTSS (SEQ ID NO: 28)
The nucleic acid sequence, or mRNA sequence, for SREBF1 isoform a (GenBank








































































TC TAAGGAAAATAAAC ATC AGAAACAAAAAAAAAAAA (SEQ ID NO: 29 )


















KLGDRRLLHDCQQMLMRLGGGTTVTSS (SEQ ID NO: 30)
The nucleic acid sequence, or mRNA sequence, for SREBFl isoform b (GenBank







































































TTTTAGAAACAAAAAAAAAAAA (SEQ ID NO: 31)
The nucleic acid sequence, or CDS, for SREBF1 isoform c (GenBank Accession No.













































TCACTTCCAGCTAA (SEQ ID NO: 32)
The nucleic acid sequence, or mRNA sequence, for SREBF1 isoform c (GenBank


















































TGAGAAAT GTACAGAAAAT AAAAAG GAAA A A A (SEQ ID NO: 33)
The amino acid sequence for SREBF1 isoform c (GenBank Accession No.















ASCYLPPAFLSAPGQQMSMLAEAARTVEKLGDHRLLLDCQQMLLRLGGGTTVTSS (SEQ ID NO: 34)
The nucleic acid sequence, or mRNA sequence, for truncated SREBF1 isoform c

















g (SEQ ID NO: 35)
The amino acid sequence for truncated SREBFl isoform c (GenBank Accession No.






HKSKSLKDLVSACGSAGGTDVAMEGV (SEQ ID NO: 36)
In one embodiment, the LMM comprises at least 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence of an
isoform of SREBFl ; e.g., SEQ ID NOs: 28, 30, 34, or 36; or differs by 1, 2, or 3 or more amino
acid residues but no more than 50, 40, 30, 20, 15, or 10 amino acid residues from the amino acid
sequence of an isoform of SREBFl; e.g., SEQ ID NOs: 28, 30, 34, or 36.
In one embodiment, the LMM comprises at least 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence of
SREBFl ; e.g., SEQ ID NO: 34; or differs by 1, 2, or 3 or more amino acid residues but no more
than 50, 40, 30, 20, 15, or 10 amino acid residues from the amino acid sequence of SREBF1,
e.g., SEQ ID NO: 34.
In another embodiment, the LMM comprises a functional fragment of SREBF1 or an
isoform thereof, e.g., a truncated SREBF1. In one embodiment, the LMM comprises a
functional fragment of SREBF1 , e.g., a functional fragment of SEQ ID NOs: 1 or 34, or a
functional fragment of an SREBF1 isoform, e.g., SEQ ID NOs: 28, 30, or 36. In one
embodiment, the LMM comprises a functional domain of SREBF1, e.g., the transactivation
domain of SREBF1 . In one embodiment, the LMM comprises the helix-loop-helix (HLH)
domain of SREBF1 . In one embodiment, the LMM comprises a functional fragment of
SREBF1 that is capable of translocating into the nucleus and/or capable of initiating
transcription of SREBFl target genes.
In one embodiment, the LMM comprises the N-terminal 410 amino acids of SREBFl
(also referred to herein as SREBF410), e.g., amino acids 1-410 of SEQ ID NO: 1. The amino
acid sequence of the N-terminal 410 amino acids of SREBFl is provided below:
MDELAFGEAALEQTLAEMCELDTAVLNDIEDMLQL INNQDSDFPGLFDAPYAGGETGDTGPS SPGANS PESFSSASL
AS SLEAFLGGPKVTPAPLSPPPSAPAALKMYPSVS PFS PGPGIKEEPVPLTILQPAAPQPSPGTLLPP SFPAPPVQL
SPAPVLGYSSLPSGFSGTLPGNTQQPPSSLPLAPAPGVLPTPALHTQVQSLASQQPLPASAAPRTNTVTSQVQQVPV
VLQPHFIKADSLLLTAVKTDAGATVKTAGI STLAPGTAVQAGPLQTLVSGGTI LATVPLWDTDKLPIHRLAAGSKA
LGSAQSRGEKRTAHNAIEKRYRS S INDKIVELKDLWGTEAKLNKSAVLRKAI DYI RFLQHSNQKLKQENLTLRSAH
KSKSLKDLVSACGSGGGTDVSMEGM ( SEQ I D NO : 2 6 )
In one embodiment, the LMM comprises at least 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence of the N-
terminal 410 amino acids of SREBFl; e.g., SEQ ID NO: 26; or differs by 1, 2, or 3 or more
amino acid residues but no more than 50, 40, 30, 20, 15, or 10 amino acid residues from the
amino acid sequence of the N-terminal 410 amino acids of SREBFl; e.g., SEQ ID NO: 26.
In another embodiment, the LMM comprises amino acids 91-410 of SREBFl, e.g., amino
acids 91-410 of SEQ ID NO: 1. The amino acid sequence ofthe amino acids at positions 91-
410 of SREBFl is provided below:




SGGGTDVSMEGM ( SEQ I D NO : 2 7 )
In one embodiment, the LMM comprises at least 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence at
positions 91-410 of SREBF1; e.g., SEQ ID NO: 27; or differs by 1, 2, or 3 or more amino acid
residues but no more than 50, 40, 30, 20, 15, or 10 amino acid residues from the amino acid
sequence at positions 91-410 of SREBF1; e.g., SEQ ID NO: 27. In one embodiment, the LMM
comprises at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%,
99%, or 100% identity with the nucleic acid sequence encoding SREBF1 or a functional
fragment thereof; e.g., encoding the amino acid sequence SEQ ID NO: 1 or a functional fragment
thereof. In one embodiment, the LMM comprises at least 50%, 55%, 60%, 65%, 70%, 75%,
80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the nucleic acid of SEQ ID
NO: 2 .
In another embodiment, the LMM comprises at least 50%, 55%, 60%, 65%, 70%, 75%,
80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SREBF2 or a functional
fragment thereof; or differs by 1, 2, or 3 or more amino acid residues but no more than 50, 40,
30, 20, 15, or 10 amino acid residues from SREBF2 or a functional fragment thereof.
In one embodiment, the LMM comprises an enzyme. In one embodiment, the LMM
comprises an enzyme that converts saturated fatty acids to unsaturated fatty acids. In one
embodiment, the LMM comprises an enzyme that converts saturated fatty acids to
monounsaturated fatty acids, e.g., fatty acids with one double bond. In one embodiment, the
LMM comprises an enzyme that converts saturated fatty acids to polyunsaturated fatty acids,
e.g., fatty acids with more than one, e.g., 2, 3, 4, 5, or more, double bonds. In one embodiment,
the LMM comprises stearoyl CoA desaturase 1 (SCDl), stearoyl CoA desaturase 2 (SCD2),
stearoyl CoA desaturase 3 (SCD3), stearoyl CoA desaturase 4 (SCD4), stearoyl CoA desaturase
5 (SCD5), an isoform thereof, or a functional fragment thereof.
SCDl is the rate limiting enzyme responsible for the conversion of saturated fatty acids
(SFA) to monounsaturated fatty acids (MUFA). Increased focus has been placed upon SCDl in
recent years due to studies linking expression of this gene to increased cell survival,
proliferation and tumorigenesis properties (Angelucci, Maulucci et al. 2015) (Igal 201 1). SCDl
has also been shown to play key roles in both cellular metabolic rate control and overall
lipogenesis. The latter is controlled through direct interactions with a major biosynthetic
pathway regulator acetyl-CoA carboxylase (ACC) as well as conversion of SFA to MUFA
which, since SFA is known to inhibit ACC, facilitates enzyme functionality to increase lipid
biosynthesis (Igal 2010). The main regulation of SCD1 is through transcriptional activation
whereby transcription factors, such as SREBF1, bind to the SRE sequence in the promoter
region of the gene. SCD1 is endogenously located in the ER as a membrane integral protein,
where SCD1 carries out its enzymatic function of catalyzing the conversion of SFA to MUFA.
Its role in conversion of SFA to MUFA (e.g., upregulation of the ratio of MUFA to SFA) can
regulate a decrease in lipid raft domains, which can in turn result in increased membrane
fluidity. This change in membrane fluidity and membrane lipid composition may also have
implications in vesicle formation and thus cellular communication and ER size or morphology
(e.g., ER expansion). Knockdown of the SCD1 gene has also been shown to upregulate the
unfolded protein response (Ariyama, Kono et al. 2010). Furthermore, SCD1 negatively
regulates cellular palmitic acid which, in turn, is a strong negative regulator of ACC. SCD1
also controls the phosphorylation status of AMP activated protein kinase (AMPK),
consequentially reducing its ability to phosphorylate and therefore inhibit ACC; a rate-limiting
enzyme in the lipid synthesizing process. Lastly, desaturation of SFA prevents its accumulation
which can cause cell death. As such, modulation of SCD1 results in increased lipid
biosynthesis, cell survival and proliferation rates. (Hagen, Rodriguez-Cuenca et al. ), (Scaglia,
Chisholm et al. 2009).







(SEQ ID NO: 3 )
















(SEQ ID NO: 4 )
In one embodiment, the LMM comprises at least 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence of
SCD1; e.g., SEQ ID NO: 3; or differs by 1, 2, or 3 or more amino acid residues but no more
than 50, 40, 30, 20, 15, or 10 amino acid residues from the amino acid sequence of SCD1, e.g.,
SEQ ID NO: 3 . In one embodiment, the LMM comprises a functional fragment of SCD1, e.g.,
a functional fragment of SEQ ID NO: 3.
In one embodiment, the LMM comprises at least 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the nucleic acid sequence
encoding SCD1 or a functional fragment thereof; e.g., encoding the amino acid sequence SEQ
ID NO: 3 or a functional fragment thereof. In one embodiment, the LMM comprises at least
50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%
identity with the nucleic acid of SEQ ID NO: 4 .
In another embodiment, the LMM comprises at least 50%, 55%, 60%, 65%, 70%, 75%,
80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence of
SCD2, SCD3, SCD4, SCD5, or a functional fragment thereof; or differs by 1, 2, or 3 or more
amino acid residues but no more than 50, 40, 30, 20, 15, or 10 amino acid residues from the
amino acid sequence of SCD2, SCD3, SCD4, SCD5, or a functional fragment thereof. In
another embodiment, the LMM comprises at least
In another embodiment, the LMM comprises a functional fragment of SCD1, SCD2,
SCD3, SCD4, or SCD5, e.g., a truncated SCD1, SCD2, SCD3, SCD4, or SCD5. In one
embodiment, the LMM comprises a functional fragment of SCD1, SCD2, SCD3, SCD4, or
SCD5, e.g., a functional fragment of SEQ ID NO: 3. In one embodiment, the LMM comprises a
functional domain of SCD1, SCD2, SCD3, SCD4, or SCD5, e.g., a domain having enzymatic
activity for converting saturated fatty acids to monounsaturated fatty acids.
Percent identity in the context of two or more amino acid or nucleic acid sequences,
refers to two or more sequences that are the same. Two sequences are "substantially identical" if
two sequences have a specified percentage of amino acid residues or nucleotides that are the
same (e.g., 60% identity, optionally 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%,
80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98%, or 99% identity over a specified region, or, when not specified, over the entire
sequence, when compared and aligned for maximum correspondence over a comparison
window, or designated region as measured using one of the following sequence comparison
algorithms or by manual alignment and visual inspection. In some embodiments, alignment may
result in gaps or inserted sequences, in which sequence similarity can be determined for specified
regions flanking the gaps or inserted sequences, or sequence similarity can be determined across
a region that includes the gaps or inserted sequences. Optionally, the identity exists over a
region that is at least about 50 amino acids or nucleotides, 100 amino acids or nucleotides, 150
amino acids or nucleotides, in length. More preferably, the identity exists over a region that is
about 200 or more amino acids or nucleotides, or about 500 or 1000 or more amino acids or
nucleotides, in length.
For sequence comparison, one sequence typically acts as a reference sequence, to which
one or more test sequences are compared. When using a sequence comparison algorithm, test
and reference sequences are entered into a computer, subsequence coordinates are designated, if
necessary, and sequence algorithm program parameters are designated. Default program
parameters can be used, or alternative parameters can be designated. The sequence comparison
algorithm then calculates the percent sequence identities for the test sequences relative to the
reference sequence, based on the program parameters. Methods of alignment of sequences for
comparison are well known in the art. Optimal alignment of sequences for comparison can be
conducted, e.g., by the local homology algorithm of Smith and Waterman, (1970) Adv. Appl.
Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch, (1970) J. Mol.
Biol. 48:443, by the search for similarity method of Pearson and Lipman, (1988) Proc. Nat'l.
Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP,
BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics
Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection
(see, e.g., Brent et al., (2003) Current Protocols in Molecular Biology). Multiple sequence
alignments can be performed by algorithms such as ClustalW, Clustal Omega, and MAFFT.
Other algorithms for comparing relationships between two or more sequences include the Hidden
Markov models. A hidden Markov Model is a model that describes the probability of a having a
particular nucleotide (or amino acid) type following another (the probability path being hidden).
It is really a probabilistic model not an algorithm. Example of an algorithm (or program
implementing the algorithm) might be HMMER (http://hmmer.org/).
Two examples of algorithms that are suitable for determining percent sequence identity
and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in
Altschul et al, (1977) Nuc. Acids Res. 25:3389-3402; and Altschul et al, (1990) J. Mol. Biol.
215:403-410, respectively. Software for performing BLAST analyses is publicly available
through the National Center for Biotechnology Information (NCBI).
PRODUCTS
Provided herein are methods and compositions for engineering or making a cell or a cell-
free expression system capable of producing high yields of a product and/or improved product
quality. Products described herein include polypeptides, e.g., recombinant proteins; nucleic acid
molecules, e.g., DNA or RNA molecules; multimeric proteins or complexes; lipid-encapsulated
particles, e.g., virus-like particles, vesicles, or exosomes; or other molecules, e.g., lipids. In an
embodiment, the product is a polypeptide, e.g., a recombinant polypeptide. In an embodiment,
the product is an exosome. For example, the recombinant polypeptide can be a difficult to
express protein or a protein having complex and/or non-natural structures, such as a next
generation biologic, e.g., a bispecific antibody molecule, a fusion protein, or a glycosylated
protein.
In embodiments, the cell or cell line generated by the methods or compositions described
herein produces a product, e.g., a recombinant polypeptide, useful in the treatment of a medical
condition, disorder or disease. Examples of medical conditions, disorders or diseases include,
but are not limited to, metabolic disease or disorders (e.g., metabolic enzyme deficiencies),
endocrine disorders (e.g., hormone deficiencies), dysregulation of hemostasis, thrombosis,
hematopoietic disorders, pulmonary disorders, gastro-intestinal disorders, autoimmune diseases,
immuno -dysregulation (e.g., immunodeficiency), infertility, transplantation, cancer, and
infectious diseases.
In embodiments, the product is an exogenous protein, e.g., a protein that is not naturally
expressed by the cell. In one embodiment, the protein is from one species while the cell is from
a different species. In another embodiment, the protein is a non-naturally occurring protein.
In other embodiments, the product is a protein that is endogenously expressed by the cell.
In one embodiment, the product is a protein that is endogenously expressed by the cell at
endogenous or natural levels. The present methods and compositions described herein are used
to increase the production and quality of the endogenous product, e.g., a naturally occurring
product that is naturally produced by the cell. In another embodiment, an exogenous nucleic acid
encoding the product, e.g., protein, is introduced to and expressed by the cell. In another
embodiment, an exogenous nucleic acid that increases the expression of a product that is
endogenously expressed by the cell is introduced into the cell. By way of example, the
exogenous nucleic acid comprises a sequence that activates the promoter (e.g., SRF promoter
sequence, see e.g., The transcription factor Ap-1 regulates monkey 20a-hydroxysteroid
dehydrogenase promoter activity in CHO cells. Nanjidsuren T, Min KS. BMC Biotechnol. 2014
Jul 30; 14:71. doi: 10.1 186/1 472-6750-1 4-71.PMID: 25073972 ) that controls the expression of
an endogenous product of the cell.
The recombinant product can be a therapeutic product or a diagnostic product, e.g., useful
for drug screening. The therapeutic or diagnostic product can include, but is not limited to, an
antibody molecule, e.g., an antibody or an antibody fragment, a fusion protein, a hormone, a
cytokine, a growth factor, an enzyme, a glycoprotein, a lipoprotein, a reporter protein, a
therapeutic peptide, or a structural and/or functional fragment or hybrid of any of these. In other
embodiments, the therapeutic or diagnostic product is a synthetic polypeptide, e.g., wherein the
entire polypeptide or portions thereof is not derived from or has any sequence or structural
similarity to any naturally occurring polypeptide, e.g., a naturally occurring polypeptide
described above.
In one embodiment, the recombinant product is an antibody molecule. In one
embodiment, the recombinant product is a therapeutic antibody molecule. In another
embodiment, the recombinant product is a diagnostic antibody molecule, e.g., a monoclonal
antibody useful for imaging techniques or diagnostic tests.
An antibody molecule, as used herein, is a protein, or polypeptide sequence derived from
an immunoglobulin molecule which specifically binds with an antigen. In an embodiment, the
antibody molecule is a full-length antibody or an antibody fragment. Antibodies and multiformat
proteins can be polyclonal or monoclonal, multiple or single chain, or intact immunoglobulins,
and may be derived from natural sources or from recombinant sources. Antibodies can be
tetramers of immunoglobulin molecules. In an embodiment, the antibody is a monoclonal
antibody. The antibody may be a human or humanized antibody. In one embodiment, the
antibody is an IgA, IgG, IgD, or IgE antibody. In one embodiment, the antibody is an IgGl,
IgG2, IgG3, or IgG4 antibody.
"Antibody fragment" refers to at least one portion of an intact antibody, or recombinant
variants thereof, and refers to the antigen binding domain, e.g., an antigenic determining variable
region of an intact antibody, that is sufficient to confer recognition and specific binding of the
antibody fragment to a target, such as an antigen. Examples of antibody fragments include, but
are not limited to, Fab, Fab', F(ab')2, and Fv fragments, scFv antibody fragments, linear
antibodies, single domain antibodies such as sdAb (either VL or VH), camelid VHH domains,
and multi-specific antibodies formed from antibody fragments such as a bivalent fragment
comprising two Fab fragments linked by a disulfide bridge at the hinge region, and an isolated
CDR or other epitope binding fragments of an antibody. An antigen binding fragment can also be
incorporated into single domain antibodies, maxibodies, minibodies, nanobodies, intrabodies,
diabodies, triabodies, tetrabodies, v-NAR andbis-scFv (see, e.g., Hollinger and Hudson, Nature
Biotechnology 23:1 126-1 136, 2005). Antigen binding fragments can also be grafted into
scaffolds based on polypeptides such as a flbronectin type III (Fn3)(see U.S. Patent No.:
6,703,199, which describes flbronectin polypeptide minibodies).
Exemplary recombinant products that can be produced using the methods described
herein include, but are not limited to, those provided in the tables below.
Table 2. Exemplary Recombinant Products
(TSH), thyrotropin
Blood Factor Vila Novo Seven
Clotting/Coagulation Factor VIII Bioclate, Helixate, Kogenate, Recombinate, ReFacto
Factors
Factor ΓΧ Benefix
Antithrombin III (AT-III) Thrombate III
Protein C concentrate Ceprotin
Cytokine/ Growth Type I alpha-interferon Infergen
factor Interferon-an3 (IFNan3) Aileron N
Interferon-pi (rIFN- β) Avonex, Rebif
Interferon-p ib (rIFN- ) Betaseron
Interferon-ylb (IFN γ) Actimmune









Antibody molecules Bevacizumab (VEGFA mAb) Avastin
Cetuximab (EGFR mAb) Erbitux
Panitumumab (EGFR mAb) Vectibix
Alemtuzumab (CD52 mAb) Campath
Rituximab (CD20 chimeric Ab) Rituxan
Trastuzumab (HER2/Neu mAb) Herceptin
Abatacept (CTLA Ab/Fc fusion) Orencia
Adalimumab (TNFa mAb) Humira
Infliximab (TNFa chimeric mAb)
Alefacept (CD2 fusion protein) Remicade
Efalizumab (CD1 l a mAb) Amevive




Other: Hepatitis B surface antigen Engerix, Recombivax HB
Fusion (HBsAg)





Spider silk, e.g., fibrion
Etanercept (TNF receptor/Fc Enbrel
fusion)
Cergutuzumab Amunaleukin
Table 3. Additional Exemplary Recombinant Products: Bispecific Formats


In one embodiment, the product differs from a polypeptide from Table 2 or 3 at no more
than 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acid residues. In another
embodiment, the product differs from a polypeptide from Table 2 or 3 at no more than 1%, 2%,
3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, or 15% of its amino acid residues.
In one embodiment, the product is a nucleic acid molecule, e.g., a DNA or RNA
molecule, or hybrid thereof. In one embodiment, the product is an origami nucleic acid
molecule, e.g., an origami DNA, in which the nucleic acid molecule has a predetermined
secondary, tertiary, or quaternary structure. In one embodiment, the origami nucleic acid
molecule has functional activity. In one embodiment, the product comprises an origami nucleic
acid molecule encapsulated in a lipid membrane. In one embodiment, the lipid membrane
comprises the cell membrane or components of the cell membrane of the host cell from which it
was produced. In one embodiment, the lipid-encapsulated DNA is as described in "Cloaked
DNA nanodevices survive pilot mission", April 22, 2014, Wyss Institute for Biologically
Inspired Engineering at Harvard University website.
Other recombinant products include non-antibody scaffolds or alternative protein
scaffolds, such as, but not limited to: DARPins, affibodies and adnectins.
Other exemplary therapeutic or diagnostic proteins include, but are not limited to any
protein described in Tables 1-10 of Leader et al., "Protein therapeutics: a summary and
pharmacological classification", Nature Reviews Drug Discovery, 2008, 7:21-39 and as
described in Walsh, "Biopharmaceutical benchmarks 2014", Nature Biotechnology, 2014,
32:992-1000 (each incorporated herein by reference); or any conjugate, variant, analog, or
functional fragment of the recombinant polypeptides described herein.
NUCLEIC ACIDS
Also provided herein are nucleic acids, e.g., exogenous nucleic acids, that encode the
lipid metabolism modulators and the recombinant products described herein. The nucleic acid
sequences coding for the desired LMM or recombinant product, e.g., recombinant polypeptides,
can be obtained using recombinant methods known in the art, such as, for example by screening
libraries from cells expressing the desired nucleic acid sequence, e.g., gene, by deriving the
nucleic acid sequence from a vector known to include the same, or by isolating directly from
cells and tissues containing the same, using standard techniques. Alternatively, the nucleic acid
encoding the LMM or recombinant polypeptide can be produced synthetically, rather than
cloned. Recombinant DNA techniques and technology are highly advanced and well established
in the art. Accordingly, the ordinarily skilled artisan having the knowledge of the amino acid
sequence of a recombinant polypeptide described herein can readily envision or generate the
nucleic acid sequence that would encode the LMM or the recombinant polypeptide.
Exemplary nucleic acid sequences encoding the LMM SREBF1 and SCD1 are provided
as SEQ ID NO: 3 and SEQ ID NO: 4, respectively, herein.
The expression of a desired polypeptide, e.g., a LMM or a recombinant polypeptide, is
typically achieved by operably linking a nucleic acid encoding the desired polypeptide or
portions thereof to a promoter, and incorporating the construct into an expression vector. The
vectors can be suitable for replication and integration into eukaryotic or prokaryotic cells.
Typical cloning vectors contain other regulatory elements, such as transcription and translation
terminators, initiation sequences, promoters, selection markers, or tags useful for regulation or
identification of the expression of the desired nucleic acid sequence.
The nucleic acid sequence encoding the LMM or recombinant polypeptide can be cloned
into a number of types of vectors. For example, the nucleic acid can be cloned into a vector
including, but not limited to a plasmid, a phagemid, a phage derivative, an animal virus, and a
cosmid. Vectors of particular interest include expression vectors, replication vectors, probe
generation vectors, and sequencing vectors. In embodiments, the expression vector may be
provided to a cell in the form of a viral vector. Viral vector technology is well known in the art
and is described, for example, in Sambrook et al, 2012, MOLECULAR CLONING: A
LABORATORY MANUAL, volumes 1 -4, Cold Spring Harbor Press, NY), and in other
virology and molecular biology manuals. Viruses, which are useful as vectors include, but are
not limited to, retroviruses, adenoviruses, adeno- associated viruses, herpes viruses, and
lentiviruses. In general, a suitable vector contains an origin of replication functional in at least
one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more
selectable markers, (e.g., WO 01/96584; WO 01/29058; and U.S. Pat. No. 6,326,193). Vectors
derived from viruses are suitable tools to achieve long-term gene transfer since they allow long-
term, stable integration of a transgene and its propagation in daughter cells.
A vector may also include, in any of the embodiments described herein, one or more of
the following: a signal sequence to facilitate secretion, a polyadenylation signal, a transcription
terminator (e.g., from Bovine Growth Hormone (BGH) gene), an element allowing episomal
replication and replication in prokaryotes (e.g. SV40 origin and ColEl or others known in the
art), and/or elements to allow selection, e.g., a selection marker or a reporter gene.
In one embodiment, the vector comprising a nucleic acid sequence encoding a
polypeptide, e.g., a LMM or a recombinant polypeptide, further comprises a promoter sequence
responsible for the recruitment of polymerase to enable transcription initiation for expression of
the polypeptide, e.g., the LMM or recombinant polypeptide. In one embodiment, promoter
sequences suitable for the methods described herein are usually associated with enhancers to
drive high amounts of transcription and hence deliver large copies of the target exogenous
mRNA. In an embodiment, the promoter comprises cytomegalovirus (CMV) major immediate
early promoters (Xia, Bringmann et al. 2006) and the SV40 promoter (Chernajovsky, Mory et al.
1984), both derived from their namesake viruses or promoters derived therefrom. Several other
less common viral promoters have been successfully employed to drive transcription upon
inclusion in an expression vector in mammalian cells including Rous Sarcoma virus long
terminal repeat (RSV-LTR) and Moloney murine leukemia virus (MoMLV) LTR (Papadakis,
Nicklin et al. 2004). In another embodiment, specific endogenous mammalian promoters can be
utilized to drive constitutive transcription of a gene of interest (Pontiller, Gross et al. 2008). The
CHO specific Chinese Hamster elongation factor 1-alpha (CHEF 1a) promoter has provided a
high yielding alternative to viral based sequences (Deer, Allison 2004).
Other promoters suitable for expression in non-mammalian cells, e.g., fungi, insect, and
plant cells, are also known in the art. Examples of suitable promoters for directing transcription
in a fungal or yeast host cell include, but are not limited to, promoters obtained from the fungal
genes of Trichoderma Reesei, methanol-inducible alcohol oxidase (AOX promoter), Aspergillus
nidulans tryptophan biosynthesis (trpC promoter), Aspergillus niger var. awamori fiucoamylase
(glaA), Saccharomyces cerevisiae galactokinase (GAL1), Kluyveromyces lactis Plac4-PBI
promoter, or those described in PCT Publication WO 2005/100573. Examples of suitable
promoters for directing transcription in an insect cell include, but are not limited to, T7 lac
promoter and polyhedrin promoter. An example of a suitable promoter for directing
transcription in a plant cell includes, but is not limited to, the cauliflower mosaic virus promoter
CaMV35S. Examples of suitable promoters for directing transcription of the nucleic acid
constructs of the present invention in a prokaryotic host cell, e.g., a bacterial cell, are the
promoters obtained from the E. coli lac operon, E. coli tac promoter (hybrid promoter, DeBoer
et al, PNAS, 1983, 80:21-25), E. coli rec A, E. coli araBAD, E. coli tetA, and prokaryotic beta-
lactamase. Other examples of suitable promoters include viral promoters, such as promoters
from bacteriophages, including a T7 promoter, a T5 promoter, a T3 promoter, an M l 3 promoter,
and a SP6 promoter.
In addition to promoters, the vectors described herein may further comprise an enhancer
region as described above; a specific nucleotide motif region, proximal to the core promoter,
which can recruit transcription factors to upregulate the rate of transcription (Riethoven 2010).
Similar to promoter sequences, these regions are often derived from viruses and are
encompassed within the promoter sequence such as hCMV and SV40 enhancer sequences, or
may be additionally included such as adenovirus derived sequences (Gaillet, Gilbert et al. 2007).
In one embodiment, the vector comprising a nucleic acid sequence encoding a
polypeptide, e.g., a LMM or a recombinant product, described herein further comprises a nucleic
acid sequence that encodes a selection marker. In one embodiment, the selectable marker
comprises glutamine synthetase (GS); dihydrofolate reductase (DHFR) e.g., an enzyme which
confers resistance to methotrexate (MTX); or an antibiotic marker, e.g., an enzyme that confers
resistance to an antibiotic such as: hygromycin, neomycin (G418), zeocin, puromycin, or
blasticidin.
In one embodiment, the vector comprising a nucleic acid sequence encoding a
recombinant product described herein comprises a selection marker that is useful in identifying a
cell or cells containing the nucleic acid encoding a recombinant product described herein. In
another embodiment, the selection marker is useful in identifying or selecting a cell or cells that
containing the integration of the nucleic acid sequence encoding the recombinant product into
the genome, as described herein. The identification of a cell or cells that have integrated the
nucleic acid sequence encoding the recombinant protein can be useful for the selection and
engineering of a cell or cell line that stably expresses the product.
In one embodiment, the vector comprising a nucleic acid sequence encoding a LMM
described herein comprises a mechanism for site-specific integration of the nucleic acid sequence
encoding the LMM. For example, the vector is compatible with the Flp-In™ system and
comprises two FRT sites (comprising a specific nucleotide sequence) that, in the presence of Flp
recombinase, directs the recombination and subsequent integration of the desired sequence, e.g.,
the nucleic acid sequence encoding the LMM, at the desired site, e.g., between the two FRT
sites, present in the genome of a Flp-In cell, e.g., a Flp-In CHO cell. Other systems used for site-
specific integration of nucleic acids encoding a desired product are known in art, e.g., the Cre-
lox recombinase system, or CRISPR/CAS -mediated strategies.
Suitable vectors for use are commercially available, and include vectors associated with
the GS Expression System™, GS Xceed™ Gene Expression System, or Potelligent® CHOKISV
technology available from Lonza Biologies, Inc, e.g., pCon vectors. Additional vectors include,
but are not limited to, other commercially available vectors, such as, pcDNA3 .1/Zeo,
pcDNA3.1/CAT, pcDNA3.3TOPO (Thermo Fisher, previously Invitrogen); pTarget, HaloTag
(Promega); pUC57 (GenScript); pFLAG-CMV (Sigma-Aldrich); pCMV6 (Origene); or pBK-
CMV/pCMV-3Tag-7/ pCMV-Tag2B (Stratagene).
CELLS AND CELL CULTURE
In one aspect, the present disclosure relates to methods and compositions for engineering
or making a cell or cell line that produces a product, e.g., a recombinant polypeptide as described
herein. In another aspect, the present disclosure relates to methods and compositions for
engineering or making a cell or cell line with improved, e.g., increased productivity and product
quality. Characteristics associated with improved productivity and product quality are described
herein, for example, in the section titled "Modulation of Lipid Metabolism".
In embodiments, the cell is a mammalian or non-mammalian cell, e.g., an insect cell, a
yeast cell, a fungal cell, a plant cell, an archaeal cell, e.g., a cell from a species of Archaea, or a
bacterial cell. In an embodiment, the cell is from human, mouse, rat, Chinese hamster, Syrian
hamster, monkey, ape, dog, duck, horse, parrot, ferret, fish or cat. In an embodiment, the cell is
an animal cell. In embodiments, the cell is a mammalian cell, e.g., a human cell or a rodent cell,
e.g., a hamster cell, a mouse cell, or a rat cell. In an embodiment, the cell is a prokaryotic eel,
e.g., a bacterial cell. In an embodiment, the cell is a species of Actinobacteria, e.g.,
Mycobacterium tuberculosis).
In one embodiment, the cell is a Chinese hamster ovary (CHO) cell. In one embodiment,
the cell is a , CHO-K1, CHOKISV, Potelligent CHOKISV (FUT8-KO), CHO GS-KO, Exceed
(CHOKISV GS-KO), CHO-S, CHO DG44, CHO DXBl 1, CHOZN, or a CHO-derived cell. The
CHO FUT8 knockout cell is, for example, the Potelligent® CHOK1 SV (Lonza Biologies, Inc.).
In another embodiment, the cell is a HeLa, HEK293, HT1080, H9, HepG2, MCF7,
Jurkat, NIH3T3, PC12, PER.C6, BHK (baby hamster kidney cell), VERO, SP2/0, NSO, YB2/0,
Y0, EB66, C127, L cell, COS, e.g., COS1 and COS7, QCl-3, , CHO-K1, CHOKISV,
Potelligent CHOKISV (FUT8-KO), CHO GS-KO, Exceed (CHOKISV GS-KO), CHO-S, CHO
DG44, CHO DXB1 1, CHOZN, or a CHO-derived cell, or any cells derived therefrom. In one
embodiment, the cell is a stem cell. In one embodiment, the cell is a differentiated form of any
of the cells described herein. In one embodiment, the cell is a cell derived from any primary cell
in culture.
In an embodiment, the cell is any one of the cells described herein that produces a
product, e.g., a product as described herein. In an embodiment, the cell is any one of the cells
described herein that comprises an exogenous nucleic acid encoding a recombinant polypeptide,
e.g., expresses a recombinant polypeptide, e.g., a recombinant polypeptide selected from Table 2
or 3 .
In an embodiment, the cell culture is carried out as a batch culture, fed-batch culture,
draw and fill culture, or a continuous culture. In an embodiment, the cell culture is an adherent
culture. In an embodiment, the cell culture is a suspension culture. In one embodiment, the cell
or cell culture is placed in vivo for expression of the recombinant polypeptide, e.g., placed in a
model organism or a human subject.
In one embodiment, the culture medium is free of serum.
Other suitable media and culture methods for mammalian cell lines are well-known in the
art, as described in U.S. Pat. No. 5,633,162 for instance. Examples of standard cell culture
media for laboratory flask or low density cell culture and being adapted to the needs of particular
cell types are for instance: Roswell Park Memorial Institute (RPMI) 1640 medium (Morre, G.,
The Journal of the American Medical Association, 199, p . 519 f . 1967), L-15 medium
(Leibovitz, A. et al., Amer. J . of Hygiene, 78, lp. 173 ff, 1963), Dulbecco's modified Eagle's
medium (DMEM), Eagle's minimal essential medium (MEM), Ham's F12 medium (Ham, R. et
al, Proc. Natl. Acad. Sc.53, p288 ff. 1965) or Iscoves' modified DMEM lacking albumin,
transferrin and lecithin (Iscoves et al., J . Exp. med. 1, p . 923 ff., 1978). For instance, Ham's F10
or F12 media were specially designed for CHO cell culture. Other media specially adapted to
CHO cell culture are described in EP-481 791.Other suitable cultivation methods are known to
the skilled artisan and may depend upon the recombinant polypeptide product and the host cell
utilized. It is within the skill of an ordinarily skilled artisan to determine or optimize conditions
suitable for the expression and production of the product, e.g., the recombinant polypeptide, to
be expressed by the cell.
METHODS FOR ENGINEERING A CELL AND PRODUCING A PRODUCT
The methods and compositions described herein are useful for engineering a cell or cell
line with improved productivity and improved product quality. In embodiments, a cell is
modified such that the lipid metabolism of the cell is modulated. For example, an exogenous
nucleic acid encoding an LMM is introduced into the cell. The cell is subsequently cultured
under conditions suitable for the expression of the LMM and LMM-mediated modulation of lipid
metabolism. The characteristics of a cell having its lipid metabolism modulated are described
herein, e.g., in the section titled "Modulation of Lipid Metabolism".
In some embodiments, the cell further comprises an exogenous nucleic acid that encodes
a product, e.g., a recombinant polypeptide. In another embodiment, the cell further comprises an
exogenous nucleic acid that increases the expression of an endogenous product. In any of such
embodiments, the exogenous nucleic acid that encodes a product or increases expression of an
endogenous product is introduced prior to the modification of lipid metabolism, e.g., the
introduction of an exogenous nucleic acid encoding a LMM described herein. Alternatively, in
other embodiments, the exogenous nucleic acid that encodes a product or increases expression of
an endogenous product is introduced after the modification of lipid metabolism, e.g., the
introduction of an exogenous nucleic acid encoding a LMM described herein. In any of the
embodiments, the product is a therapeutic or diagnostic protein. In any of the embodiments, the
product is selected from Table 2 or 3 .
Methods for genetically modifying or engineering a cell to express a desired polypeptide
or protein, e.g., an LMM described herein or a product described herein, are well known in the
art, and include, for example, transfection, transduction (e.g., viral transduction), or
electroporation.
Physical methods for introducing a nucleic acid, e.g., an exogenous nucleic acid or vector
described herein, into a host cell include calcium phosphate precipitation, lipofection, particle
bombardment, microinjection, electroporation, and the like. Methods for producing cells
comprising vectors and/or exogenous nucleic acids are well-known in the art. See, for example,
Sambrook et al, 2012, MOLECULAR CLONING: A LABORATORY MANUAL, volumes 1 -
4, Cold Spring Harbor Press, NY).
Chemical means for introducing a nucleic acid, e.g., an exogenous nucleic acid or vector
described herein, into a host cell include colloidal dispersion systems, such as macromolecule
complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water
emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system for use as a
delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle). Other
methods of state-of-the-art targeted delivery of nucleic acids are available, such as delivery of
polynucleotides with targeted nanoparticles or other suitable sub-micron sized delivery system.
Nucleic acids containing the sequence for a desired polypeptide, e.g., a LMM and/or
product described herein, are delivered into a cell and can be integrated into its genome via
recombination. The resulting recombinant cells are then capable of stable expression of the
desired polypeptide, e.g., a LMM and/or product described herein, thus enabling consistent and
efficient protein production over long periods of time. Several advantages accompany stable
integration of a gene of interest including the fact that only a single DNA delivery process is
required to induce prolonged expression since the gene of interest is simultaneously replicated
with host chromosomes; this means that the gene is transferred from one generation to the next
without the necessity for additional machinery. This also, in theory, produces a more consistent
product and yield across batch-to-batch fermentations. In line with this, stable expression
methods are capable of generating high product yields compared to those generated without
a modification that modulates lipid metabolism described herein, e.g., introduction of an
exogenous nucleic acid encoding a LMM.
Protocols to establish recombinant cell lines that stably overexpress the desired
polypeptides, e.g., a LMM and/or product described herein, typically involve integration of
linearized DNA (usually plasmid based) at random sites into the host genome facilitated by
random recombination. Site specific protocols have also been developed and implemented which
promote integration of an expression cassette at specific regions of the host genome
(O'Gorman, Fox et al. 1991). These protocols often exploit recombinases capable of site
specific recombination, and include, but are not limited to, the Flp-In™ system (e.g., utilizing
Flp-In CHO cells), CHOK1SV Flp cell line (Lonza) (as described in Zhang L. et al. (2015).
Biotechnol. Prog. 31:1645-5; incorporated by reference herein in its entirety), or the Cre-lox
system.
As described above, in some embodiments, the vector comprising a nucleic acid encoding
a product and/or a LMM, further comprises a selection marker to facilitate selection of
successfully expressing cells from a transfected pool (Browne, Al-Rubeai 2007). Although
numerous selection methods are commercially available, the most commonly used of these are
methotrexate (MTX) and Lonza's glutamine synthetase (GS) system (Bebbington, Renner et
al. 1992, Lai, Yang et al. 2013). Dihydrofolate reductase (DHFR) is a protein responsible for
the conversion of folic acid to tetrahydro folate and is necessary for essential biosynthetic
pathways that produce glycine, purines, and thymidylic acid. MTX can be used to inhibit DHFR
activity and inclusion of DHFR in a stably transfected culture can therefore be used to select for
stably integrated cells; only those cells successfully expressing sufficient recombinant DHFR
will survive selection using MTX (Cacciatore, Chasin et al. 2010). Another selection method
commonly employed is the use of GS; an enzyme responsible for the synthesis of glutamine
from glutamate and ammonia and, since glutamine is vital for mammalian cell survival, cells
lacking sufficient GS will not survive in culture. Initially the addition of methionine
sulphoximine (MSX), an inhibitor of GS, ensures that the presence of endogenous GS in
CHOK1 SV cells is not adequate to maintain cell survival and therefore only cells expressing
additional GS brought about through stable integration of a recombinant construct survive the
selection process. Lonza and others have now established CHO host cell lines in which the
endogenous GS gene has been knocked down/out such that all cells perish that are not
successfully integrated with the construct of interest without the presence of exogenous
glutamine in the media (Fan, Kadura et al. 2012). Many other selection methods are available
which elicit a resistance to a particular selection agent such that only cells harboring the
resistance gene will survive the selection process; these include hygromycin, neomycin,
blasticidin and zeocin (Browne, Al-Rubeai 2007). In embodiments, the vector comprising an
exogenous nucleic acid encoding a LMM and the vector comprising an exogenous nucleic acid
encoding a product, e.g., a recombinant polypeptide as described herein, further comprise
different selection markers.
Following the successful recovery of stably expressing cell pools, the isolation of
individual clones, originating from a single cell, facilitates' the selection of cell lines that are
capable of high product yields and quality, or the cell lines with the highest capability of high
product yields and high quality product. Differences in cellular properties are likely associated
with heterogeneity observed in cells and both the number and specific integration site(s) of
recombinant DNA. Clonal screening properties have therefore been developed to rapidly
assess multiple clones and subsequently select high expressing cells. Fluorescence Activated Cell
Sorting (FACS) is a method which can rapidly sort cells based on fluorescence intensity and
therefore can be employed to select for high expressing clones. Several protocols have been
established which involve fluorescent tagging of the protein of interest (Powell, Weaver 1990),
fluorescent tagging of cell surface molecules co-expressed with the recombinant gene
(Holmes, Al-Rubeai 1999) and detection of fluorescence intensity based on eGFP expression co-
expressed with the gene of interest (Meng, Liang et al. 2000). A high fluorescence intensity
observed with these methods suggests a high level of recombinant protein production and thus
these cells can be preferentially selected from a recombinant cell pool. FACS-based selection
methods to isolate high expressing recombinant clones are more suited to recombinant
products which remain associated with the cell and, since mammalian expressed biotherapeutic
recombinant protein products are secreted, methods have been developed which are more
appropriate for the selection of clones for secreted recombinant proteins. For example,
ClonePix is an automated colony selection method which picks clones grown on a semi-solid
media based on secretion of recombinant products into the media surrounding the colony and
associating with Fluorescin Isothiocyanante (FrTC) therefore creating a fluorescent halo around
the colonies (Lee, Ly et al. 2006). Clones are selected based on the fluorescence intensity of the
halo surrounding the colony. Many other clone selection protocols have been established which
rapidly isolate recombinant cells based on desired biological properties with particular interest
on productivity and are reviewed in Browne and Al-Rubeai (Browne, Al-Rubeai 2007).
Expansion of a clone selected as described herein results in the production of a cell line.
In one embodiment, the methods described herein produce a cell with improved
productivity. Improved productivity or production capacity of a cell includes a higher yield or
amount of product that is produced, and/or an increased rate of production (as determined by the
yield or amount of product produced over a unit of time). In one embodiment, improvement of
the productivity of a cell, e.g., the capacity to produce a product, results in an increase, e.g., a
1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%,
70%, 75%, 80%, 85%, 90%, 95%, or 99% increase; or a 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-
fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 50-fold, or 100-fold, or more increase in the amount,
level, or quantity of product produced, e.g., compared to the amount, level, or quantity of product
produced by a cell that does not have a lipid metabolism pathway modulated. In one
embodiment, improvement of the productivity of a cell, e.g., the rate of production of the
product, results in an increase, e.g., a 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%,
40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% increase; or a 1-
fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 50-fold, or 100-
fold, or more increase in the rate of production of the product, e.g., compared to the rate of
production of the product produced by a cell that does not have a lipid metabolism pathway
modulated.
The methods described herein for engineering a cell produce a high production cell or a
high production cell line. A high production cell or cell line is capable of producing higher
yields of a recombinant polypeptide product than compared to a reference cell or a cell that has
not been selected or engineered by the methods described herein. In an embodiment, a high
production cell line is capable of producing 100 mg/L, 200 mg/L, 300 mg/L, 400 mg/L, 500
mg/L, 600 mg/L, 700 mg/L, 800 mg/L, 900 mg/L,l g/L, 2 g/L, 3 g/L, 4 g/L, 5g/L, 10 g/L, 15
g/L, 20 g/L, 25 g/L, 30 g/L, 35 g/L, 40 g/L, 45 g/L, 50 g/L, 55 g/L, 60 g/L, 65 g/L, 70 g/L, 75
g/L, 80 g/L, 85 g/L, 90 g/L, 95 g/L, or 100 g/L or more of a product, e.g., a recombinant
polypeptide product. In an embodiment, a high production cell line is produces 100 mg/L, 200
mg/L, 300 mg/L, 400 mg/L, 500 mg/L, 600 mg/L, 700 mg/L, 800 mg/L, 900 mg/L, 1 g/L, 2 g/L,
3 g/L, 4 g/L, 5g/L, 10 g/L, 15 g/L, 20 g/L, 25 g/L, 30 g/L, 35 g/L, 40 g/L, 45 g/L, 50 g/L, 55 g/L,
60 g/L, 65 g/L, 70 g/L, 75 g/L, 80 g/L, 85 g/L, 90 g/L, 95 g/L, or 100 g/L or more of a product,
e.g., a recombinant polypeptide product. The quantity of product produced may vary depending
on the cell type, e.g., species, and the product, e.g., recombinant polypeptide, to be expressed.
By way of example, a high production CHO cell that expresses a monoclonal antibody may be
capable of producing at least 1 g/L, 2 g/L, 5g/L, 10 g/L, 15 g/L, 20 g/L, or 25 g/L of a
monoclonal antibody.
Described herein are methods and compositions that may be particularly useful for the
expression of products that are difficult to express or produce in cells or cell-free systems using
the conventional methods presently known in the art. As such, a production cell line producing
such difficult to express products, e.g., next generation biologies described herein, may produce
at least 1 mg/L, 5 mg/L, 10 mg/L, 15 mg/L, 20 mg/L, 25 mg/L, 30 mg/L, 35 mg/L, 40 mg/L, 45
mg/L, 50 mg/L, 55 mg/L, 60 mg/L, 65 mg/L, 70 mg/L, 75 mg/L, 80 mg/L, 85 mg/L, 90 mg/L, 95
mg/L, or 100 mg/L or more. Production capacity (e.g., yield, amount, or quantity of product or
rate of production of product) achieved by the methods and compositions described herein for
difficult to express proteins can be increased by 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%,
80%, 90%, 95%, 99%, or more, or 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold,
or 100-fold or more, in comparison to the production capacity of a cell or system that does not
have a modification that modulates lipid metabolism as described herein.
Assays for quantifying the amount, level, or quantity of product produced or secreted,
e.g., secreted into the culture media, include protein quantification assays, such as the Bradford
protein assay, SDS-PAGE analysis, immunoblotting, e.g., western blot, and automated means,
e.g., using a nanodrop device. Other methods for measuring increased protein production are
well-known to those skilled in the art. For example, an increase in recombinant protein
production might be determined at small-scale by measuring the concentration in tissue culture
medium by ELISA (Smales et al. 2004 Biotechnology Bioengineering 88:474-488). It can also
be determined quantitatively by the ForteBio Octet, for example for high throughput
determination of recombinant monoclonal antibody (mAb) concentration in medium (Mason et
al. 2012 Biotechnology Progress 28:846-855) or at a larger-scale by protein A HPLC (Stansfield
et al. 2007 Biotechnology Bioengineering 97:410-424). Other methods for determining
production of a product, e.g., a recombinant polypeptide described herein, can refer to specific
production rate (qP) of the product, in particular the recombinant polypeptide in the cell and/or to
a time integral of viable cell concentration (rVC). In an embodiment, the method for
determining production includes the combination of determining qP and IVC. Recombinant
polypeptide production or productivity, being defined as concentration of the polypeptide in the
culture medium, is a function of these two parameters (qP and rVC), calculated according to
Porter et al. (Porter et al. 2010 Biotechnology Progress 26:1446-1455). Methods for measuring
protein production are also described in further detail in the Examples provided herein.
In one embodiment, the methods described herein produce a cell with improved product
quality. In one embodiment, improvement of the quality of the product results in the increase,
e.g., a 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%,
65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99%, or more, increase in product quality; or a 1-
fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 50-fold, or 100-
fold, or more increase, in product quality, e.g., as compared to the amount, level, or quantity of
product produced by a cell that does not have a lipid metabolism pathway modulated. Such
increases in product quality can be exemplified, for example, by one or more of the following:
i) an increase in the amount or quantity of non-aggregated product (or a decrease in
the amount or quantity of aggregated product);
ii) an increase in the amount or quantity of properly folded or assembled product (or
a decrease in the amount or quantity of misfolded, unfolded, partially assembled,
or non-assembled product), or an increase in the ratio of properly folded or
assembled product to unfolded, misfolded, partially assembled, or non-assembled
product;
iii) an increase in the amount or quantity of full-length product (or a decrease in
fragmentation of the product);
iv) an increase in the desired post-translational modifications (or a decrease in
unmodified or incorrectly modified product);
v) an increase or decrease in glycan heterogeneity (e.g., for glycosylated products);
vi) an increase in the amount or quantity of functional product (or a decrease in the
amount or quantity of a nonfunctional or dysfunctional product), or an increase in
the ratio of function to nonfunctional or dysfunctional product; and/or
vii) an increase or decrease in disulfide bond scrambling (e.g., an increase or decrease
the desired isoform or structure as a result to increased or decreased disulfide
bond scrambling, e.g., for antibody molecule products).
Methods for measuring product quality, e.g., the improvement of the product quality, of a
cell or cell line generated as described herein are known in the art. In one embodiment, methods
for determining the fidelity of the primary sequence of the expressed recombinant polypeptide
product are known in the art, e.g., mass spectrometry. An increase in the amount or
concentration of properly folded product, e.g., expressed recombinant polypeptide, can be
determined by circular dichroism or assessing the intrinsic fluorescence of the expressed
recombinant polypeptide. An increase in the amount or concentration of functional product can
be tested using various functional assays depending on the identity of the recombinant product,
e.g., recombinant polypeptide. For example, antibodies can be tested by the ELISA or other
immunoaffinity assay. Other methods for determining an increase in product quality, e.g.,
determining aggregation, post-translational modifications, disulfide bond scrambling, can be
assessed by size exclusion chromatography, high performance liquid chromatography, dynamic
light scattering (DLS) approaches, and protein electrophoresis (PAGE) methods.
In an embodiment, the methods for producing a product, e.g., as described herein,
comprise providing a cell engineered to comprise a modification that modulates lipid
metabolism, as described above. In one embodiment, the cell comprising a modification that
modulates lipid metabolism further comprises an exogenous nucleic acid encoding a product,
e.g., a recombinant polypeptide as described herein. In one embodiment, the exogenous nucleic
acid encoding a product, e.g., a recombinant polypeptide described herein is introduced to the
engineered cell comprising a modification that modulates lipid metabolism. In another
embodiment, the exogenous nucleic acid encoding a product, e.g., a recombinant polypeptide
described herein, is introduced to a cell prior to the introduction of an exogenous nucleic acid
encoding a LMM as described herein. The exogenous nucleic acid encoding a product further
comprises a selection marker, for efficient selection of cells that stably express, e.g., overexpress,
the product as described herein.
In some embodiments, additional steps may be performed to improve the expression of
the product, e.g., transcription, translation, and/or secretion of the product, or the quality of the
product, e.g., proper folding and/or fidelity of the primary sequence. Such additional steps
include introducing an agent that improves product expression or product quality. In an
embodiment, an agent that improves product expression or product quality can be a small
molecule, a polypeptide, or a nucleic acid that encodes a polypeptide that improves protein
folding, e.g., a chaperone protein. In an embodiment, the agent that assists in protein folding
comprises a nucleic acid that encodes a chaperone protein, e.g., BiP, PD1, or EROl
(Chakravarthi & Bulleid 2004; Borth et al. 2005; Davis et al. 2000). Other additional steps to
improve yield and quality of the product include overexpression of transcription factors such as
XBP1 and ATF6 (Tigges & Fussenegger 2006; Cain et al. 2013; Ku et al. 2008) and of lectin
binding chaperone proteins such as calnexin and calreticulin (Chung et al. 2004). Overexpression
of the agents that assist or improve protein folding, product quality, and product yield described
herein can be achieved by introduction of exogenous nucleic acids encoding the agent. In
another embodiment, the agent that improves product expression or product quality is a small
molecule that can be added to the cell culture to increase expression of the product or quality of
the product, e.g., DMSO. In one embodiment, culturing the cells at a lower temperature, e.g.,
1°C, 2°C, 3°C, 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, or 10°C lower, than the temperature that the cells
are normally grown can improve productivity.
Any of the methods described herein can further include additional selection steps for
identifying cells that have high productivity or produce high quality products. For example,
FACS selection can be utilized to select specific cells with desired characteristics, e.g., higher
expression of a protein folding proteins, e.g., chaperones.
In one aspect, the disclosure provides methods that include a step for recovering or
retrieving the recombinant polypeptide product. In embodiments where the recombinant
polypeptide is secreted from the cell, the methods can include a step for retrieving, collecting, or
separating the recombinant polypeptide from the cell, cell population, or the culture medium in
which the cells were cultured. In embodiments where the recombinant polypeptide is within the
cell, the purification of the recombinant polypeptide product comprises separation of the
recombinant polypeptide produced by the cell from one or more of any of the following: host cell
proteins, host cell nucleic acids, host cell lipids, and/or other debris from the host cell.
In embodiments, the process described herein provides a substantially pure protein
product. As used herein, "substantially pure" is meant substantially free of pyrogenic materials,
substantially free of nucleic acids, and/or substantially free of endogenous cellular proteins
enzymes and components from the host cell, such as polymerases, ribosomal proteins, and
chaperone proteins. A substantially pure protein product contains, for example, less than 25%,
20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of contaminating endogenous
protein, nucleic acid, or other macromolecule from the host cell.
Methods for recovering and purification of a product, e.g., a recombinant polypeptide, are
well established in the art. For recovering the recombinant polypeptide product, a physical or
chemical or physical-chemical method is used. The physical or chemical or physical-chemical
method can be a filtering method, a centrifugation method, an ultracentrifugation method, an
extraction method, a lyophilization method, a precipitation method, a chromatography method or
a combination of two or more methods thereof. In an embodiment, the chromatography method
comprises one or more of size-exclusion chromatography (or gel filtration), ion exchange
chromatography, e.g., anion or cation exchange chromatography, affinity chromatography,
hydrophobic interaction chromatography, and/or multimodal chromatography.
EXAMPLES
The invention is further described in detail by reference to the following experimental
examples. These examples are provided for purposes of illustration only, and are not intended to
be limiting unless otherwise specified. Thus, the invention should in no way be construed as
being limited to the following examples, but rather, should be construed to encompass any and
all variations which become evident as a result of the teaching provided herein.
Without further description, it is believed that one of ordinary skill in the art can, using
the preceding description and the following illustrative examples, make and utilize the
compounds of the present invention and practice the claimed methods. The following working
examples specifically point out various aspects of the present invention, and are not to be
construed as limiting in any way the remainder of the disclosure.
Example 1: Generation of Stable Cells Overexpressing a Lipid Metabolism Modulator
In order to investigate the effect of overexpression of two lipid metabolism modulators,
SCD1 and SREBFl, in CHO cells, these genes were successfully cloned and stably integrated
into adherent CHO Flp-In cells using a site directed approach, and into suspension GS knockout
(GSKO) CHO cells using a random integration approach.
Molecular Cloning of SCO1 and SREBFl containing FRT vectors
Molecular cloning was carried out in order to generate FRT based vectors which
facilitate the expression of SCD1 and SREBFl proteins both with and without a V5/His tag at
the C-terminus of each protein. The use of these vectors, in conjunction with Thermo Fisher's
commercially available Flp-In host CHO cell pool enabled site specific integration of the genes
of interest to generate stable CHO adherent cell pools. The primers described in Table 4 were
used in a Phusion® Polymerase based PCR reaction to amplify these genes such that double
stranded DNA fragments were produced flanked by the restriction sites also detailed in Table 4 .
SCD1 and SREBFl genes were amplified from Mouse P19 derived cDNA and Origene mouse
cDNA clone ( CBI accession no. NM_01 1480), respectively.
Following successful amplification of the target genes, double restriction digests were
undertaken on FRT-V5 vectors as well as the previously generated PCR products of the genes of
interest using the appropriate restriction enzymes. Ligations were incubated overnight before
subsequent transformations and miniprep purification was carried out on the resulting colonies.
Generation ofSCDl and SREBFl O erexpressing Adherent Fl -In CHO Cells
The aforementioned FRT-based constructs were used in conjunction with Thermo
Fisher's commercially available adherent Flp-In CHO cells to generate stable cell pools. FRT
vectors containing the genes of interest and an empty FRT construct (used to generate a control
cell pool) were co-transfected with recombinase containing pOG44 vector into Flp-In cells.
Recombinase sites present in the FRT vectors and Flp-In CHO genome initiate site specific
recombination and successful clones can be isolated using hygromycin as a selection agent.
Stably expressing recombinant CHO adherent cell pools in a site specific manner were generated
according to the manufacturer's instructions, e.g., as described in the Thermo Fisher's Flp-In
manual, e.g., available from the Thermo Fisher's references and protocols website. This method
was used to generate and recover control, SCD1 -V5, and SREBFl -V5 Flp-In CHO polyclonal
cell pools.
Molecular Cloning of SCD1 and SREBFl into pcDNA3.1 Vectors
Expression vectors were generated to stably integrate, and therefore overexpress, in
industrially relevant CHO suspension cells with one of SCD1, SREBFl or a truncated
SREBFl gene. The pcDNA3.1V5-His/TOPO vector consists of an appropriate CMV promoter
and downstream multiple cloning site, facilitating expression of the gene of interest, while also
including elements enabling expression of a neomycin gene which can be utilized for selection
of successful clones following integration of DNA into the genome.
Initially, the Phusion® PCR protocol was used to amplify SCD1, SREBFl and a
SREBFl truncation using the primers indicated in Table 4, designed so that restriction sites were
simultaneously added to the flanks of the resulting PCR products. The previously generated
SCD1-FRT vector was used as a template to amplify the SCD1 genes while Origene mouse
cDNA (NCBI accession no. NM_01 1480) was used to amplify the SREBFl gene and its
truncation. The SREBFl truncation hereby referred to as SREB410, codes for a 410 amino acid
long polypeptide sequence, which includes the helix- loop-helix (HLH) domain of SREBFl. This
domain is endogenously cleaved from the full-length protein allowing migration of this fragment
to the nucleus and subsequent gene transcription activation as previously outlined. Primers were
designed to amplify this region with the aim to express a protein (encoded by this sequence)
which is localized directly in the nucleus and thus to carry out its function as a transcriptional
activator without the need for endogenous processing.
Double restriction digests were carried out on purified PCR products as appropriate (see
Table 4), and pcDNA3.1 /V5-His/TC)PO, where primers amplified a gene with no stop codon, in
order to allow read through into an in-frame sequence encoding a V5 and His tag. The resulting
DNA fragments were ligated to yield vectors containing SCD1, SREBF1 or SREB410 genes
with a V5-His tag. These reactions were transformed and mini preps were carried out on a
number of the resulting colonies. Restriction digests were carried out and the resulting DNA
fragments were run on an agarose gel to ascertain which samples were successful.
Generation of SCD1 and SREBF1 Overexpressing Suspension GSKO CHO Cells
Suspension CHOK1SV GS-KO cell pools grown in chemically-defined, protein and
serum-free media, stably transfected with the previously synthesized pcDNA3.1V5-His/TOPO
derived constructs were generated in order to investigate the effect of constitutive expression of
the inserted genes in an industrially relevant cell line. In order to achieve this, stable
integration was carried out using Lonza's CHOK1SV GS-KO host cell line. Initially, SCD1-
V5, SREBF1-V5, SREB410-V5 and control (empty pcDNA3.1V5-His/TOPO) constructs were
linearized by overnight digestion with Pvul restriction enzyme (NEB). Following linearization,
DNA was purified using ethanol precipitation and CHOK1SV GS-KO cells were electroporated
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using 20 µg DNA and 1 x 10 viable cells before immediate transfer to T75 flasks containing
CD-CHO medium (Thermo Fisher) at 37°C to make a final volume of 20 mL. Flasks were
placed in a humidified static incubator at 37°C with a 5% C02 in air atmosphere for 24 hours.
A concentrated stock of G418 (Melford) selection agent was diluted in CD-CHO medium
and 5 mL of this stock was added to the T75 flasks and gently mixed to yield a final
concentration of 750 µg/mL in a 25 mL total volume. Cell counts were performed every 3-4
days to determine growth and culture viability and 750 g/ml G418 in CD-CHO media was
renewed approximately every 6 days by centrifugation and resuspension. Cells were transferred
to 125 mL Erlenmeyer flasks and routine suspension cell culture was established once
cells had reached a concentration of 2 x 10^ viable cells/mL.
Table 4 : Summary of primer sequences
Example 2: Expression Analysis of LMM in Stable Cells Overexpressing a . M
Following the establishment of stable Flp-In CHO cell pools stably integrated with either
a control (empty pcDNA5 FRT), SCD1-V5 or SREBF1 V5, immunofluorescence was
undertaken to confirm both the expression of the stably exogenous integrated genes and
additionally the intracellular location of the expressed proteins. Control, SCD1-V5 and SREBF1-
V5 cell lines were seeded at 2 x 105 viable cells per well in a 24 well plate in Ham Nutrient Mix
F12 medium supplemented with 10% FBS. Samples were methanol-fixed and first exposed to
anti-V5 antibody (produced in mouse- Sigma V8012) and successively anti-mouse FITC
secondary conjugate (raised in goat-Sigma F0257). Furthermore, the cells were exposed to DAPI
stain (10 µg/mL working stock) in order to stain cellular DNA thus highlighting the nuclei. The
resulting immunofluorescent images are shown in Figure 1.
The presence of the FITC stains in SCD1-V5 and SREBF1-V5 cell lines shows that the
exogenous/recombinant genes were successfully expressed and, moreover, the cellular
localization of SCD1-V5 and SREBF1-V5 proteins was clearly evident. Constitutively expressed
SCD1-V5 protein was present and abundant throughout the cell, with the images showing their
localization to be in the cytoplasm and in the ER. Conversely, the SREBF1-V5 protein was
expressed to a much lower amount, but it was very prominently located at the peri-nucleus
forming a ring around the nuclei. It is important to consider that the V5 epitope sequence was
added to the 3 ' end of the gene and, because of the natural regulation of SREBF1, specific
domains are cleaved and relocated within the cell. The mature, cleaved bHLH (basic helix loop
helix) region is of particular importance as it is responsible for transcriptional activation of many
genes with implications on lipid biosynthesis and conformation. Because this region is encoded
at the 5' end of the gene, this region would not be detected upon staining of the 3' V5 tag and
thus it is impossible to determine whether any of the constitutively expressed, cleaved portion of
the translated protein is present in the imaged cells.
Staining of intracellular V5-tagged stable proteins was carried out to determine the
presence of SCD1-V5 and SREBF1-V5 in engineered CHOK1SV GS-KO suspension cell lines.
In order to adhere these cells to a coverslip in a 24 well plate, coverslips were first treated with
poly-L-lysine and cells were seeded at 2 x 105 cells per well and left to incubate at 37°C in a 5%
C0 2 environment static humidified incubator overnight. Following methanol fixing and
permeablisation, anti-V5 (produced in mouse - Sigma V8012) was conjugated with anti-mouse
TRITC (produced in goat- T5393) secondary antibody. The resulting images are shown in Figure
2 .
Western blots were performed using an anti-V5 antibody, an anti-mouse HRP conjugated
secondary antibody, and the appropriate detection system, was used to further confirm
expression of the lipid constructs with the V5 tag. Equivalent amounts of total protein
(determined using the Bradford assay) were loaded for SDS-PAGE followed by western blotting
onto nitrocellulose. The resulting blots are shown in Figures 3A, 3B, and 3C with the V5 tag
only detected in those cells expressing the SCD1 construct. However, the low levels of
expression achieved with the SREBF1 construct may explain the lack of detection of V5 in cell
lines expressing this construct.
Example 3: Growth Characteristics of Stable Cells Overexpressing a . M
In this example, the growth characteristics, such as viable cell counts, cell number, and
culture viability were assessed in two different cell lines engineered to overexpress LMMs, a
CHO Flp-In™ and the CHOK1SV GS-KO (Lonza Biologies) cell lines. The LMM-engineered
cell lines were generated as described in Example 1. Control cell lines were engineered to
express an empty V5 tagged expression vector. An eGFP encoding expression vector was
transfected into the LMM-engineered cell lines by electroporation. Electroporations were carried
out using 1 x 107 viable LMM-engineered Flp-In CHO cells or CHOK1SV GS-KO cells and 20
g of plasmid DNA (eGFP encoding expressing vector) and these cells were diluted to a final
volume of about 20 or 32 mL in Ham Nutrient Mix F12 medium. Viable cell concentrations were
determined using a ViCell cell counter and recorded at 24, 48, 72, and 96 hours post transfection
of the eGFP encoding expression vector.
The results for the Flp-In™ cells engineered to express SCDl and SREBFl are shown in
Figure 4 . Cells overexpressing SCDl and SREBFl generally showed some increase in the
viable cell concentation compared to control cells across all time points.
The results for the CHOK1SV GS-KO cells engineered to express SCDl, SREBFl, and
SREBF410 are shown in Figures 5A and 5B. Viable cell concentration compared to total cell
cocentration are shown in Figure 5A, with the viable cell concentration represented by the lower
column, and the whole column representing the total number of cells counted. As shown in
Figure 5A, expression of LMM (SCDl and SREBFl) results in a general increase in viable and
total cell numbers across all time points. By 48, 72 and 96 hours, viable and total cell
concentration were significantly higher in SCDl and SREBF 1-engineered cells. At 96 hours,
viable cell counts for SCDl and SREBFl -engineered cells were more than 1 x 106 cells/mL
higher than control cells. Culture viability was also calculated and shown in Figure 5B. The
LMM-engineered cells generally showed an increase in culture viability as compared to control
cells.
Example 4: Increased eGFP Induced Fluorescence in Stable Cells Overexpressing a LMM
In this example, the production capacity for producing a recombinant protein was
assessed in the CHO-Flp-In™ and the CHOK1SV GS-KO cell lines that were engineered to
stably express LMMs, as described in Example 1. The LMM-engineered cells were transfected
with an eGFP encoding expression vector as described in Example 3, and production capacity
was assessed by measuring the amount of eGFP produced by flow cytometry at 24, 48, 72, and
96 hours after transfection. A FACSCalibur (BD Biosciences) instrument was used to measure
the eGFP-mediated fluorescence of the cells and generate the data shown here.
Production of eGFP was measured in Flp-In cells engineered to express V5-tagged SCD1
and SREBF1. Figures 6A, 6B, and 6C show the median fluorescence, the geometric mean
fluorescence, and the arithmetic mean fluorescence, respectively, of the LMM-engineered Flp-In
cells recorded using flow cytometry at the specified time points. These values are increased in
SCD1 overexpressing cells for median fluorescence, geometric mean fluorescence, and
arithmetic mean fluorescence, thereby demonstrating that cells stably expressing SCD1 are
capable of producing more eGFP compared to the control cells.
Production of eGFP was measured in CHOK1SV GS-KO cells engineered to express V5-
tagged SCD1, SREBF1, and SREBF410. Median fluorescence is shown in Figure 7A and
geometric mean fluorescence is shown in Figure 7B. Increased median fluorescence and
geometric mean fluorescence was observed for cells engineered to overexpress SREBF1 .
In order to account for differences in cell concentration and proliferation properties
observed in CHOK1SV GS-KO derived cell lines. Total fluorescence per mL of culture was
calculated by multiplying the measured arithmetic mean fluorescence by the total cell
concentration (xlO6 per mL), and the calculated values are shown in Figure 7C. As shown in
Figure 7C, SCD1 overexpressing cells produced a significantly increased amount of recombinant
protein (eGFP) at 24 hours after transfection as compared to control cells. SREBF1
overexpressing cells generally produced an increased amount of eGFP at all time points tested as
compared to control cells, and significantly increased amounts at 72 and 96 hours after
transfection.
Collectively, these data show that engineering cells to express an LMM, such as SCD1
and SREBF1, increases production capacity of a transiently expressed recombinant protein such
as eGFP. Furthermore, as demonstrated by the fluorescence measured, the cells produced
increased correctly folded and functional eGFP as compared to cells that did not have a
modification that modulates lipid metabolism, thereby demonstrating that modulation of lipid
metabolism increases both production yields and quality.
Example 5: Improved Productivity in Stable Cells Overexpressing an LMM
Similar to the experiments described in Example 4, cell lines that stably express LMMs
were assessed for production capacity of different products, such as a model IgG4 antibody
molecule (referred to herein as antibody A) and a fusion protein (referred to herein as Fc fusion
protein or FP).
Flp-In cells stably expressing V5-tagged SCD1 and SREBF1 (engineered as described in
Example 1) were electroporated with expression vectors encoding antibody A or a Fc fusion
protein. Following electroporation, the quantity of recombinant antibody A and FP in culture
supernatant was determined at 24, 48, 72, and 96 hours after electroporation by western blotting.
An anti-heavy chain primary antibody, an anti-rabbit-HRP conjugated secondary antibody, and
the appropriate detection reagent were used to detect antibody A (Figure 8A) and the Fc fusion
protein (Figure 9A). Average fold change in production of the antibody A and Fc fusion protein
was determined by Protein A HPLC, and shown in Figures 8B and 9B, respectively. Cell lines
expressing exogenous SCD1 demonstrated increased productivity compared to the control cell
lines with both recombinant proteins. Furthermore, this effect was consistent across the 24, 48,
72, and 96 hour time points analyzed.
Lonza's CHOK1SV GS-KO (Xceed™ ) cells stably expressing the SCD1, SREBF1, and
SREBF410 constructs (engineered as described in Example 1) were transiently transfected with
two recombinant proteins; a model IgG4 (antibody A) and an Fc fusion protein. Following
electroporation, the quantity of recombinant antibody A and FP in culture supernatant was
determined every 24 hours up to 96 hours by western blotting using an anti-heavy chain primary
antibody, an anti-rabbit-HRP conjugated secondary antibody, and the appropriate detection
reagent (Figures 10A and 11A). Average fold change in production of the antibody A and Fc
fusion protein was determined by Protein A HPLC, and shown in Figures 10B and 11B,
respectively. CHOK1SV GS-KO cells lines expressing exogenous SCD1, SREBF1, and
SREBF410 demonstrated increased productivity compared to the control cell lines with both
recombinant proteins (Figures 10B and 1IB). Furthermore, this effect was consistent across the
48, 72, and 96 hour time points analyzed.
Lonza's CHOK1SV GS-KO (Xceed™ ) cells stably expressing the SCD1, SREBF1, and
SREBF410 constructs (engineered as described in Example 1) were stably transfected with two
recombinant proteins; a model IgG4 (antibody A) and an Fc fusion protein. Figure 15A and 16A
show volumetric productivity of antibody A and FC fusion protein respectively at 48, 96, 144
and 192 hours after initial seeding at 0.2 x 106 viable cells/ml. Results show that the SCDl
overexpressing cell pools improve the absolute yield of both recombinant molecules.
Furthermore, upon calculations to include cell numbers, the specific productivity of both
recombinant molecules was also greatly increased in SCDl overexpressing cell pools (Figure
15B and 16B).
These results collectively show that engineering cells to express an LMM, such as SCDl ,
SREBFl, and a functional fragment of SREBFl (SREBF410) increases production capacity of
transiently expressed recombinant proteins, such as antibody molecules and fusion proteins.
Example 6: Improving Established Production Cell Lines
Examples 4 and 5 demonstrate that cell lines stably expressing LMMs have improved
production when transiently expressing a recombinant product, such as a GFP, an antibody
molecule, or a fusion protein. In this example, analysis was performed to determine the effect of
LMMs on the enhancing existing stable yields of a recombinant product in established cell lines.
CH0121 cells that have been previously engineered to stably express a model IgG4
antibody molecule (antibody A) were used. Constructs encoding V5-tagged SCDl, SREBFl and
a truncated SREBFl (SREBF410) were transiently expressed in the antibody A-stably
expressing cells. Control cells were transfected with an empty V5 tag vector. Supernatants from
the cells were harvested at 48, 72, and 168 hours. Western blot analysis was performed to
determine the amount of antibody A produced by using an anti-heavy chain primary antibody
(Sigma 19764), followed by anti-rabbit HRP conjugated secondary antibody (Sigma A6154), and
the results are shown in Figure 12A. As shown, expression of LMMs SCDl and SREBF410
resulted in an increase in the amount of antibody A produced by the cells as compared to control
at both 48 and 72 hours after introduction of the LMMs. Supernatants from cells were subjected
to Coomassie analysis to show the amount of antibody A produced after 168 hours after
introduction of the LMMs, and demonstrate that LMM transient expression (SCDl and
SREBF410) resulted in improved production of the recombinant protein (Figure 12B). Figure 13
shows quantitative analysis of antibody A using protein A HPLC highlighting a marked increase
in the average product titre following transient transfections with SCDl and SREB410
containing plasmids at 48, 72, 96 and 144 hours post transfection. Figure 14 shows quantitative
analysis of the FC fusion protein using protein A analysis to determine product titres and viable
cell numbers to determine specific productivity. This data shows an increase in the average
specific productivity of cells transiently transfected with vectors containing LMM elements and
the SREBFl containing construct yields the highest average value.
These results show that modulation of the lipid metabolism in established cell lines can
further improve production capacity compared to established yields.
Example 7 : Improved Productivity by Simultaneous Introduction of Recombinant Genes
and LMMs
Plasmids/constructs were generated which comprise of genes for appropriate expression
of both an exemplary immunocytokine and either a control (no LMM), SCDl, SREBFl or
SREB41 1 (SREBFl derived sequences were CHO specific; NM_00 1244003, SEQ ID NOs: 34
and 36). These constructs were then used to transiently transfect Lonza's CHOK1SV GS-KO
cells. Figure 17A shows western analysis of supernatants harvested at 48 and 96 hours post
transfection. The supernatant samples used were reduced and the transient product was detected
by probing with an anti-heavy chain primary antibody and HRP conjugated anti-rabbit secondary
to highlight a native heavy chain (lower band) and cytokine fused heavy chain (upper band).
Inclusion of SCDl, SREBFl and SREB41 1 genes in the transfected construct resulted in an
increase in both band intensities at both 48 and 96 hours post transfection. Furthermore, figure
17B shows quantitative analysis of samples obtained at 96 hours post transfection using protein
A analysis. Relative abundances of the immunocytokine support the data presented in western
analysis (Figure 17A).
These data show that the simultaneous inclusion of an LMM, such as SCDl, SREBFl,
and a functional fragment of SREBFl (SREBF41 1), with recombinant product genes can
improve production capacity.
What is claimed is:
1. A method for producing a product, e.g., a polypeptide, e.g., a recombinant
polypeptide, by a cell, comprising:
i) providing a cell comprising a modification that modulates lipid metabolism, and
ii) culturing the cell, e.g., under conditions suitable for modulation of lipid
metabolism by the modification,
thereby producing the product, e.g., polypeptide, e.g., recombinant polypeptide.
2 . The method of claim 1, wherein the cell comprises an exogenous nucleic acid that
encodes the polypeptide, e.g., a polypeptide selected from Table 2 or 3 .
3 . The method of either of claims 1 or 2, wherein the modification provides increased
production or improved quality of the polypeptide as compared to a cell not having the
modification.
4 . The method of any of claims 1-3, comprising forming, in the cell, an exogenous
nucleic acid encoding a lipid metabolism modulator (LMM) or an exogenous LMM, and
optionally wherein forming comprises introducing an exogenous nucleic acid encoding a lipid
metabolism modulator, e.g., which increases the expression of an endogenous nucleic acid
encoding a LMM.
5 . The method of any of claims 1-4, comprising a second modification that modulates
lipid metabolism and wherein the second modification comprises a second exogenous nucleic
acid encoding a second LMM, e.g., a LMM different from the LMM of the first modification.
6 . The method of claim 5, wherein:
i) the second exogenous nucleic acid and the first exogenous nucleic acid are disposed on
the same nucleic acid molecule, or
ii) the second exogenous nucleic acid and the first exogenous nucleic acid are disposed
on different nucleic acid molecules.
7 . The method of either of claims 5 or 6, wherein the second modification provides
increased production or improved quality of the product, as compared to a cell not having the
second modification.
8. The method of any of claims 5-7, comprising forming, in the cell, a second exogenous
nucleic acid encoding a second LMM or a second exogenous LMM, and optionally wherein
forming comprises introducing the second exogenous nucleic acid encoding a second LMM, e.g.,
which increases the expression of an endogenous nucleic acid encoding a LMM.
9 . The method of any of claims 1-8, wherein modulating lipid metabolism comprises,
e.g., results in, altering one or more of the following (e.g., as compared with a cell not having a
modification):
i) the expression (e.g., transcription and/or translation) of a component involved in a
lipid metabolism pathway;
ii) the activity (e.g., enzymatic activity) of a component involved in a lipid
metabolism pathway;
iii) the amount of lipids (e.g., phospholipids, or cholesterol) present in a cell;
iv) the amount of lipid rafts or rate of lipid raft formation;
v) the fluidity, permeability, and/or thickness of a cell membrane (e.g., a plasma
membrane, a vesicle membrane, or an organelle membrane);
vi) the conversion of saturated lipids to unsaturated lipids or conversion of
unsaturated lipids to saturated lipids;
vii) the amount of saturated lipids or unsaturated lipids, e.g., monounsaturated lipids;
viii) the composition of lipids in the cell to attain a favorable composition that
increases ER activity;
ix) the expansion of the ER (e.g., size of the ER, the ER membrane surface, or the
amounts of the proteins and lipids that constitute and/or reside within the ER);
x) the expansion of the Golgi (e.g., the number and size of the Golgi, the Golgi
surface, or the number or amounts of proteins and molecules that reside within the
Golgi);
xi) the amount of secretory vesicles or the formation of secretory vesicles;
xii) the amount or rate of secretion of the product;
xiii) the proliferation capacity, e.g., the proliferation rate;
xiv) culture viability or cell survival;
xv) activation of membrane receptors;
xvi) the unfolded protein response (UPR);
xvii) the yield or rate of production of the product;
xviii) the product quality (e.g., aggregation, glycosylation heterogeneity, fragmentation,
proper folding or assembly, post-translational modification, or disulfide bond
scrambling); and /or
cell growth/proliferation or cell specific growth rate.
10. The method of any of claims 1-9, wherein:
i) production of the product, e.g., recombinant polypeptide, is increased by 1-fold, 2-fold,
5-fold, 10-fold, 20-fold, 50-fold, 100-fold, e.g., as compared to the level or quantity of product
produced by a cell without modulation of the lipid metabolism, or
ii) the quality of the product, e.g., recombinant polypeptide, is increased, e.g., by 1-fold,
2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, e.g., as compared to the quality of product
produced by a cell without modulation of the lipid metabolism.
11. The method of any of claims 1-10, wherein:
i) the modification results in modulating, e.g., increasing, the expression or activity of a
lipid metabolism gene product, e.g., a lipid metabolism gene product selected from Table 1,
ii) the expression or activity of a transcription regulator, e.g., a transcription factor, that
modulates the expression of a lipid metabolism gene product, e.g., a lipid metabolism gene
product selected from Table 1, is upregulated by the modification, or
iii) both (i) and (ii).
12. The method of any of claims 1-1 1, wherein the lipid metabolism modulator
comprises:
i) a transcription regulator, e.g., a transcription factor, that mediates, e.g., upregulates, the
expression of a lipid metabolism gene product, e.g., a lipid metabolism gene product selected
from Table 1; SREBFl; or SREBF2, or a functional fragment or analog of any of the same, or
ii) SCDl or a functional fragment thereof.
13. The method of any of claims 1-12, wherein the modification results in modulating,
e.g., increasing, one or more of de novo lipogenesis, fatty acid re-esterification, fatty acid
saturation or desaturation, fatty acid elongation, and phospholipid biosynthesis.
14. The method of any of claims 1-13, wherein the LMM comprises an enzyme that
modulates, e.g., increases, the conversion of saturated to unsaturated, e.g., monounsaturated,
lipids, and optionally wherein the enzyme comprises SCDl, SCD2, SCD3, SCD4, or SCDl, or a
functional fragment or analog thereof.
15. The method of claim 11, wherein the modification comprises:
i) a lipid metabolism gene product, e.g., a lipid metabolism gene product selected from
Table 1, or a functional fragment or analog thereof, or
ii) a cis or trans regulatory element that increases the expression of a nucleic acid that
encodes a lipid metabolism gene product, e.g., a lipid metabolism gene product selected from
Table 1.
16. The method of claim 11, wherein the LMM comprises one or more gene products, or
functional fragments or analogs thereof, from:
i) the lipid biosynthesis (lipogenesis) pathway, e.g., a gene product selected from Table 1,
ii) the fatty acid re-esterification pathway, e.g., a gene product selected from Table 1,
iii) the phospholipid biosynthesis pathway, e.g., a gene product selected from Table 1, or
iv) the fatty acid saturation or desaturation pathway, e.g., a gene product selected from
Table 1.
17. The method of claim 11, wherein the lipid metabolism modulator comprises:
i) at least 60, 70, 80, 90, 95, 98, 99 or 100% identity with the amino acid sequence of
SREBFl; e.g., SEQ ID NOs:l or 34, or a functional fragment thereof, e.g., SEQ ID NOs: 26, 27,
or 36; or differs by 1, 2, or 3 or more amino acid residues but no more than 50, 40, 30, 20, 15, or
10 amino acid residues from the amino acid sequence of SREBFl, e.g., SEQ ID NOs: 1 or 34, or
a functional fragment thereof, or a functional fragment thereof, e.g., SEQ ID NOs: 26, 27, or 36,
or
ii) at least 60, 70, 80, 90, 95, 98, 99 or 100% identity with the amino acid sequence of
SCD1; e.g., SEQ ID NO:3, or a functional fragment thereof; or differs by 1, 2, or 3 or more
amino acid residues but no more than 50, 40, 30, 20, 15, or 10 amino acid residues from the
amino acid sequence of SCD1, e.g., SEQ ID NO: 3, or a functional fragment thereof.
18. The method of claim 11, wherein the nucleic acid encoding the lipid metabolism
modulator comprises at least 60, 70, 80, 90, 95, 98, 99 or 100% identity with any of the nucleic
acid sequences selected from SEQ ID NOs: 2, 4, or 32.
19. The method of any of claims 11-18, wherein the nucleic acid encoding the lipid
metabolism modulator comprises a plasmid or a vector, and optionally wherein the nucleic acid
encoding the lipid metabolism modulator is introduced into the cell by transfection or
transduction.
20. The method of any of claims 11-19, wherein the nucleic acid encoding the lipid
metabolism modulator:
i) is integrated into the chromosomal genome of the cell, and optionally wherein the
LMM is stably expressed, or
ii) is not integrated into the chromosomal genome of the cell, and optionally wherein the
LMM is transiently expressed.
2 1. The method of any of claims 1-20, further comprising introducing to the cell an
exogenous nucleic acid encoding the product, e.g., polypeptide, e.g., recombinant polypeptide,
wherein:
i) the exogenous nucleic acid encoding the recombinant polypeptide is introduced after
step i) or step ii), or
ii) the exogenous nucleic acid encoding the recombinant polypeptide is introduced prior
to step i) or step ii).
22. The method of claim 21, wherein the recombinant polypeptide is:
i) a therapeutic polypeptide,
ii) an antibody molecule, e.g., an antibody or an antibody fragment thereof, a monoclonal
antibody, or a bispecific molecule, or
iii) selected from Table 2 or 3 .
23. The method of either of claims 2 1 or 22, wherein the exogenous nucleic acid
encoding the recombinant polypeptide is:
i) integrated into the chromosomal genome of the cell, or
ii) not integrated into the chromosomal genome of the cell.
24. The method of any of claims 1-23, wherein the cell is:
i) a eukaryotic cell, e.g., an animal cell, a mammalian cell, a human cell, a rodent cell, a
CHO cell, a yeast cell, an insect cell, or a plant cell, or
ii) a prokaryotic cell.
25. The method of any of claims 1-24, wherein the cell is a selected from HeLa,
HEK293, H9, HepG2, MCF7, Jurkat, NIH3T3, PC12, PER.C6, BHK, VERO, SP2/0, NSO,
YB2/0, EB66, C127, L cell, COS, e.g., COS1 and COS7, QCl-3, , CHO-K1, CHOKISV,
Potelligent CHOKISV (FUT8-KO), CHO GS-KO, Exceed (CHOKISV GS-KO), CHO-S, CHO
DG44, CHO DXB1 1, CHOZN, or a CHO-derived cell.
26. The method of any of claims 1-25, wherein the method further comprises introducing
a modification to the cell that improves ER processing capacity (ER expansion) or secretion,
optionally wherein improving ER processing capacity (ER expansion) comprises introducing a
nucleic acid encoding PD 1, BiP, ERO, or XBP 1, and optionally wherein improving secretion
comprises modulating SNARE machinery, e.g., introducing a nucleic acid encoding a SNARE
component.
27. The method of any of claims 1-26, further comprising one or more of the following:
i) obtaining from the cell, or a descendent of the cell, the polypeptide,
ii) obtaining from medium conditioned by the cell, or a descendent of the cell, the
polypeptide,
iii) separating the polypeptide from at least one cellular or medium component, or
iv) analyzing the polypeptide, e.g., for activity or for the presence of a structural moiety.
28. A method of engineering a cell having increased production capacity and/or improved
quality of production comprising introducing to the cell an exogenous nucleic acid encoding a
lipid metabolism modulator, thereby engineering a cell having increased production capacity
and/or improved quality of production.
29. The method of claim 28, wherein the exogenous nucleic acid encoding a lipid
metabolism modulator is introduced to the cell by transfection, transduction, e.g., viral
transduction, electroporation, nucleofection, or lipofection, and optionally wherein the
exogenous nucleic acid encoding a lipid metabolism modulator is integrated into the
chromosomal genome of the cell.
30. The method of either of claims 28 or 29, further comprising introducing to the cell an
exogenous nucleic acid encoding a recombinant polypeptide, wherein the exogenous nucleic acid
encoding a recombinant polypeptide is introduced:
i) prior to introducing the exogenous nucleic acid encoding the LMM, or
ii) after introducing the exogenous nucleic acid encoding the LMM.
3 1. The method of any of claims 28-30, wherein:
i) the production capacity, e.g., the amount of recombinant polypeptide produced, is
increased by 1-fold, 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, e.g., as compared to the
production capacity of a cell without modulation of the lipid metabolism,
ii) the quality of production, e.g., the quality of the recombinant polypeptide, is increased
by, e.g., 1%, 5%, 10%, 15%,20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 70%, 75%,
80%, 85%, 90%, 85%, or 100%, or more, , e.g., as compared to the quality of production of a
cell without modulation of the lipid metabolism, or
iii) both (i) and (ii).
32. The method of any of claims 28-3 1, wherein the LMM is selected from a group
consisting of SREBF1, SREBF2, SCD1, SCD2, SCD3, SCD4, SCD5, and wherein the cell
produces a product, e.g., a polypeptide, e.g., recombinant polypeptide as provided in Table 2 or
3, or a functional fragment thereof.
33. A cell produced by any of claims 28-32.
34. A cell comprising an exogenous nucleic acid encoding a lipid metabolism modulator
(LMM), optionally wherein the exogenous nucleic acid encoding a lipid metabolism modulator
is integrated into the chromosomal genome of the cell.
35. The cell of claim 34, wherein the cell is a eukaryotic cell, e.g. a CHO cell or a human
cell.
36. The cell of either of claims 34 or 35, wherein the cell is selected from the group
consisting of CHO-Kl, CHOKISV, Potelligent CHOKISV (FUT8-KO), CHO GS-KO, Exceed
(CHOKISV GS-KO), CHO-S, CHO DG44, CHO DXB1 1, CHOZN, or a CHO-derived cell.
37. The cell of claim 34, wherein the LMM modulates the expression of a product, e.g., a
Next generation biologic (NGB) described herein, e.g., a bispecific antibody, a fusion protein, or
a glycosylated protein.
38. The engineered cell of claim 37, wherein the LMM is selected from a group
consisting of SREBFl, SREBF2, SCDl, SCD2, SCD3, SCD4, and SCD5, or a functional
fragment thereof.
39. The engineered cell of claim 37, wherein the LMM alters one or more characteristics
of the cell selected from the group consisting of:
i) the expression (e.g., transcription and/or translation) of a component involved in a
lipid metabolism pathway;
ii) the activity (e.g., enzymatic activity) of a component involved in a lipid
metabolism pathway;
iii) the amount of lipids (e.g., phospholipids, or cholesterol) present in a cell;
iv) the amount of lipid rafts or rate of lipid raft formation;
v) the fluidity, permeability, and/or thickness of a cell membrane (e.g., a plasma
membrane, a vesicle membrane, or an organelle membrane);
vi) the conversion of saturated lipids to unsaturated lipids or conversion of
unsaturated lipids to saturated lipids;
vii) the amount of saturated lipids or unsaturated lipids, e.g., monounsaturated lipids;
viii) the composition of lipids in the cell to attain a favorable composition that
increases ER activity;
ix) the expansion of the ER (e.g., size of the ER, the ER membrane surface, or the
amounts of the proteins and lipids that constitute and/or reside within the ER);
x) the expansion of the Golgi (e.g., the number and size of the Golgi, the Golgi
surface, or the number or amounts of proteins and molecules that reside within the
Golgi);
xi) the amount of secretory vesicles or the formation of secretory vesicles;
xii) the amount or rate of secretion of the product;
xiii) the proliferation capacity, e.g., the proliferation rate;
xiv) culture viability or cell survival;
xv) activation of membrane receptors;
xvi) the unfolded protein response (UPR);
xvii) the yield or rate of production of the product;
xviii) the product quality (e.g., aggregation, glycosylation heterogeneity, fragmentation,
proper folding or assembly, post-translational modification, or disulfide bond
scrambling); and /or
xix) cell growth/proliferation or cell specific growth rate.
40. The engineered cell of any of claims 37-39, wherein the cell is selected from a group
consisting of:
i) a eukaryotic cell, e.g., a CHO cell selected from the group consisting of CHO-K1,
CHOKISV, Potelligent CHOKISV (FUT8-KO), CHO GS-KO, Exceed (CHOKISV GS-KO),
CHO-S, CHO DG44, CHO DXB1 1, CHOZN, or a CHO-derived cell,
ii) a prokaryotic cell,
iii) an insect cell,
iv) a plant cell,
v) a yeast cell, or
vi) an algae cell.
4 1. A CHO cell engineered to express a lipid metabolism modulator (LMM), wherein the
LMM modulates one or more characteristics of the CHO cell, wherein the engineered CHO cell
is selected based on modulation of one or more characteristics selected from the group consisting
of:
i) the expression (e.g., transcription and/or translation) of a component involved in a
lipid metabolism pathway;
ii) the activity (e.g., enzymatic activity) of a component involved in a lipid
metabolism pathway;
iii) the amount of lipids (e.g., phospholipids, or cholesterol) present in a cell;
iv) the amount of lipid rafts or rate of lipid raft formation;
v) the fluidity, permeability, and/or thickness of a cell membrane (e.g., a plasma
membrane, a vesicle membrane, or an organelle membrane);
vi) the conversion of saturated lipids to unsaturated lipids or conversion of
unsaturated lipids to saturated lipids;
vii) the amount of saturated lipids or unsaturated lipids, e.g., monounsaturated lipids;
viii) the composition of lipids in the cell to attain a favorable composition that
increases ER activity;
ix) the expansion of the ER (e.g., size of the ER, the ER membrane surface, or the
amounts of the proteins and lipids that constitute and/or reside within the ER);
x) the expansion of the Golgi (e.g., the number and size of the Golgi, the Golgi
surface, or the number or amounts of proteins and molecules that reside within the
Golgi);
xi) the amount of secretory vesicles or the formation of secretory vesicles;
xii) the amount or rate of secretion of the product;
xiii) the proliferation capacity, e.g., the proliferation rate;
xiv) culture viability or cell survival;
xv) activation of membrane receptors;
xvi) the unfolded protein response (UPR);
xvii) the yield or rate of production, e.g., expression level, of the product, e.g., a Next
generation biologic (NGB), e.g., a bispecific antibody; a fusion protein; or a
glycosylated protein;
xviii) the product quality (e.g., aggregation, glycosylation heterogeneity, fragmentation,
proper folding or assembly, post-translational modification, or disulfide bond
scrambling); and /or
xix) cell growth/proliferation or cell specific growth rate.
42. The engineered CHO cell of claim 4 1, wherein the LMM is selected from a group
consisting of SREBFl, SREBF2, SCDl, SCD2, SCD3, SCD4, and SCD5, or a functional
fragment thereof.
43. The engineered CHO cell of claim 41, wherein the product, e.g., NGB, is selected
from a group consisting of a bispecific antibody molecule, a fusion protein, and a glycosylated
protein.
44. The engineered CHO cell of claim 4 1, wherein the CHO cell is selected from the
group consisting of CHO-Kl, CHOKISV, Potelligent CHOKISV (FUT8-KO), CHO GS-KO,
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